

REVIEW ARTICLE

Key Words: fibromyalgia, FMS, pain, chronic pain, dorsal horn, neuroendocrine, controlled trials, transporter binding, sleep

Understanding the Fibromyalgia Syndrome

Srinivas G. Rao, MD, PhD, Judith F. Gendreau, MD,
and Jay D. Kranzler, MD, PhD

ABSTRACT ~ The fibromyalgia syndrome (FMS) is the most frequent cause of chronic, widespread pain. This review, which is targeted at the psychiatry and psychopharmacology communities, summarizes the state-of-the-art as it relates to both the pathophysiology and treatment of FMS. Toward this end, the anatomy and physiology of pain pathways are summarized, followed by a review of the altered biology of pain processing, neurotransmitter function, and neuroendocrine systems in FMS. The categories of current drugs employed to treat the disorder are detailed, along with a critical review of the literature supporting such use. *Psychopharmacology Bulletin*. 2007;40(4):24-67.

INTRODUCTION

The fibromyalgia syndrome (FMS) is the most frequent cause of chronic, widespread pain, with estimates of world-wide prevalence ranging from 0.5 to 5.0%.^{1,2} FMS is second only to osteoarthritis (OA) as the most common diagnosis among patients seen in rheumatology offices, and it is diagnosed approximately 4 times more frequently in women than in men. There are presently no diagnostic tests for fibromyalgia. Rather, the accepted diagnostic criteria require that spontaneous pain be present for over 3 months duration along the spine and in all four quadrants of the body, and pain upon digital palpation must be elicited at 11 out of 18 "tender points" (Figure 1).³ It should be appreciated that a number of treatable and/or life-threatening conditions may present with symptoms that resemble those of FMS, and these obviously need to be excluded before a definitive diagnosis is made.⁴


Patients with FMS display quantitative abnormalities in pain perception under experimental conditions, in the form of both *allodynia*—perceiving pain even from a non-painful stimulus, such as light touch—and *hyperalgesia*—an augmentation of pain processing in which a painful stimulus is magnified and perceived with higher intensity than it would be by a normal volunteer.⁵⁻¹⁰ These data are suggestive of a state of sensitized pain perception in FMS.^{8,11} In theory, such a

Dr. Rao is chief scientific officer at Cypress Biosciences, Inc.; Dr. Gendreau is director of medical affairs and part-time consultant to Cypress Bioscience, Inc.; Dr. Kranzler is chairman of the board and chief executive officer of Cypress Bioscience, Inc., in San Diego, CA.

To whom correspondence should be addressed: Srinivas G. Rao, MD, PhD, Cypress Bioscience, Inc., 4350 Executive Drive, Suite 325, San Diego, California 92121; Telephone: (858) 452-2323; Telefax: (858) 452-1222; E-mail: srao@cypressbio.com

FIGURE 1

FIBROMYALGIA TENDER POINTS



25

Rao, Gendreau,
and Kranzler

Rao, Gendreau, and Kranzler. *Psychopharmacology Bulletin*. Vol. 40. No. 4. 2007.

state can conceptually result from widespread changes within the target organs (i.e., skin, muscles, etc.), from alterations in nociceptive processing within the central nervous system, or some combination of both processes. Indeed, some early theories of FMS pathophysiology posited that FMS pain was a result of peripheral abnormalities, particularly alterations in skeletal muscle.¹² However, more recent studies have generally failed to confirm the presence of such alterations,¹²⁻¹⁵ though it is recognized that peripheral insults may play a role in instigating or maintaining FMS.^{11,16} On the other hand, several lines of inquiry support the role of altered central pain processing (ie, “central sensitization”) as underlying the pain of FMS, as will be discussed in detail below.

Though not reflected in the diagnostic criteria, FMS patients typically present with a number of symptoms beyond pain. Fatigue is cited as a significant cause of morbidity for the vast majority of FMS patients.¹⁷

Subjective sleep disturbances, particularly in the form of nonrestorative sleep, are reported to occur in over three-quarters of FMS patients.¹⁸ A majority of patients complain of difficulties with concentration and memory, a situation that has been termed “fibro fog.”¹⁹ Approximately 20–40% of individuals with FMS have an identifiable current mood disorder such as depression or anxiety disorder at the time of diagnosis, with a lifetime incidence as high as 70%.^{20–23} Taken on the whole, FMS can result in severe disability, comparable to that seen in other rheumatic diseases such as OA or rheumatoid arthritis, despite the absence of “objective” findings.^{24,25}

FMS has been included as one of the so-called “unexplained clinical conditions”^{26,27} or “functional somatic syndromes”^{28,29} that are characterized more by symptoms, suffering, and disability than by consistent tissue abnormality. As such, there have been suggestions that FMS and other related syndromes may represent a form of somatization disorder.³⁰ Nonetheless, FMS is treated today primarily within the medical model. It is most often diagnosed in the primary care setting and almost half of the office visits are to internal medicine and family practitioners. 1998 National Ambulatory Medical Care Survey.³¹ Rheumatologists are the leading specialty group seeing FMS patients, representing 16% of office visits. The remainder of office visits are to a variety of tertiary care providers, including pain centers, physical medicine specialists, and psychiatrists.

FMS remains a controversial diagnosis almost 15 years after the establishment of the diagnostic criteria. Some authors express concern that placing the label of FMS on these individuals promotes helplessness and disability.^{32–34} Others focus on the legal and social consequences of identifying FMS as a disorder that can be caused by certain exposures (eg, motor vehicle accidents), thus promoting litigation.³⁵ Others question the validity of the criteria for diagnosis, especially the requirement for a certain number of tender points.^{36,37}

Overview

This paper is intended as follow-up to a previous review by the same authors,³⁸ detailing some of the changes in the FMS landscape that have occurred in the intervening 2 years. Overall, FMS has attracted a great deal of attention recently, both within the lay and scientific press. The overall validity of FMS as a therapeutic indication has been augmented by the FDA’s recognition of the significant unmet medical need that FMS represents.^{39,40} This need has also lead to interest in FMS on the part of pharmaceutical companies; indeed, the results of several relatively large, well-controlled industry-sponsored clinical trials have recently been published and will be detailed below.

Like the predecessor publication, the primary goal of the current article is to provide a summary of the state-of-the art pertaining to FMS, with psychiatrists as the target audience, focusing primarily its pathophysiology and current therapeutic options. Historically, pain has not been the typical purview of psychiatrists, despite the fact that a relationship between pain and affective disorders has been known to exist for some time.⁴¹ However, this connection has come under increasing scrutiny lately.^{42,43} Of particular relevance to the practicing psychiatrist is the finding that over 50% of patients that are ultimately diagnosed with depression present initially only with a somatic symptoms.⁴⁴ Furthermore, the inadequate treatment of pain makes the task of treating comorbid depression much more challenging.⁴⁵ Conversely it should be noted that cognitive behavioral therapy has been used successfully in some patients with FMS and other related chronic pain conditions, even in the absence of an overt affective disorder.^{27,46-48}


The body of the review will be divided into three parts: First, as FMS is a clinical demonstration of the existing links between pain sensation, the stress response, and mood, we briefly describe the neuroanatomy, pharmacology, and connectivity of the relevant pathways. Second, we review the neurochemical and neuroendocrinological differences that exist in FMS patients and compare these observations to other conditions where appropriate. Finally, we summarize the literature on the effectiveness of drugs in treating FMS and will try, where possible, to tie the empirical findings back to both normal physiology and FMS pathophysiology.

PAIN PATHWAYS: REVIEW

It has been recognized for some time that nociception is not a passive, uni-directional process;⁴⁹ rather, there is a complex interaction between ascending and descending pathways with the ability to dramatically alter the relationship between stimulus and response (see Figure 2).⁵⁰ Nociceptive input from the periphery is relayed via peripheral afferent fibers (PAF) to the dorsal horn of the spinal cord. After significant local processing, signals are sent to higher centers, and these impulses form the basis for pain perception. The two major descending pain-modulating systems employ the neurotransmitters serotonin (5-HT) and norepinephrine (NE), and originate from the rostral ventromedial medulla (RVM) and the dorsolateral pontine catecholamine cell groups (DLP), respectively. At the level of the spinal cord, the projections from the RVM appear to have both pro- and anti-nociceptive effects, while the pontine projections appear to be mainly anti-nociceptive. These two systems are tightly interconnected,⁵¹ and their respective anti-nociceptive effects appear to be additive under some circumstances.⁵²

FIGURE 2

THE ASCENDING AND DESCENDING PAIN PATHWAYS



28

Rao, Gendreau,
and Kranzler

Rao, Gendreau, and Kranzler. *Psychopharmacology Bulletin*. Vol. 40. No. 4. 2007.


AQ2

As shown in Figure 3, the main excitatory transmitter from the PAF to the dorsal horn neuron is glutamate (Glu) acting at several postsynaptic receptors, including those of the NMDA variety. In addition, neurokinins including substance P (SP), calcitonin gene related peptide (CGRP) and neurokinin A (NKA) are co-localized with Glu. The descending pathways from the RVM and DLP carrying 5-HT and NE, respectively, modulate the activity of the PAF terminals. For example, NE acting at α_2 receptors can inhibit the PAF terminal and cause a reduction in glutamate and SP release, and a similar effect can be observed with activation of mu opioid receptors located on the PAF terminals. Conversely, 5-HT acting at 5-HT₃ receptors can increase the release of these neurotransmitters. Finally, increasing local 5-HT concentrations or a 2 mediated neurotransmission within the RVM itself has been shown to be anti-nociceptive.⁵³⁻⁵⁴

The dorsal horn neuron is also subject to NE, 5-HT, and opiate input, acting respectively at α_2 , 5-HT_{1A}, and mu opioid receptors. Note that all of these receptors are predominantly inhibitory, and while 5-HT has excitatory effects on the PAF terminals, it can inhibit the dorsal horn both directly (via 5-HT_{1A} activation) or indirectly (through activation of a GABAergic interneuron).

FIGURE 3

THE DORSAL HORN



Rao, Gendreau, and Kranzler. *Psychopharmacology Bulletin*. Vol. 40. No. 4. 2007.

Chronic Pain: Changes in Nociceptive Processing

Over the past decade, it has been recognized that chronic pain is quite different from acute pain, clinically and pharmacologically.⁵⁵ As described below, a number of alterations occurring both within the central nervous system and at the periphery may contribute to the chronic pain state. One can envision that disabling one or more anti-nociceptive pathways or augmenting a pro-nociceptive pathway can lead to a state of central sensitization. “Wind-up” is an example of this phenomenon which occurs at the PAF-dorsal horn neuron synapse. The term refers to a specific pattern of augmentation in the response to a dorsal horn neuron that results from tonic, peripheral nociceptive input. Such augmentation is thought to underlie certain components of allodynia and hyperalgesia.^{56–58} A number of studies suggest that NMDA and NK₁ receptor activation represents critical steps in initiating “wind-up” and related phenomena in dorsal horn neurons.^{56,59–66}

The descending systems may also play a role in central sensitization. For example, recent studies have demonstrated that reduced spinal NE outflow from the DLP results in a chronic hyperalgesic state in laboratory animals.⁶⁶ Likewise, a significant body of research has implicated the RVM in maintaining the hyperalgesic state. For example, inactivation of

the RVM (by lesion, injection of lidocaine, or spinal transection) can reverse the allodynia and hyperalgesia seen in animal models of chronic pain.⁶⁷ Further, the application of cholecystokinin (CCK-B) receptor antagonists reverses the mechanical allodynia seen in animal models of chronic neuropathic pain.⁶⁸ Finally, in addition to its role within the dorsal horn in initiating wind-up, direct injection of NMDA antagonists into the RVM reverses the hyperalgesia present in several chronic pain paradigms,⁷⁰⁻⁷¹ suggesting that NMDA receptors at the level of the RVM may also play a role in maintaining a hyperalgesic state.

LABORATORY FINDINGS IN FMS PATIENTS

Like many psychiatric diseases, the study of FMS is hampered today by the lack of well-validated animal models that can serve as proxies for study of the human condition, although it should be noted that significant strides are being made toward this end.⁷²⁻⁷³ Nonetheless, based on an understanding of normal physiology, and armed with clues from similar diseases in humans, much insight can be gained from monitoring the status of biochemical pathways or physiological processes that may be affected by the disease process. A focus on the former, such as measurement of a neurotransmitter level in cerebrospinal fluid (CSF), facilitates the design of experiments that are relatively simple and easy to control, with the outcome potentially providing a target for drug discovery. However, the result from any single analysis may be difficult to interpret, as it may represent only one piece of a complex and dynamic puzzle at a single point in time. In contrast, tests of physiological function, such as brain imaging or sleep monitoring, provide a more integrative perspective. However, the data obtained may be of less practical use for the discovery or development of pharmaceutical compounds.

While there are hundreds of papers in the literature attempting to identify quantifiable, objective, and meaningful biological differences in FMS patients, many are designed as “pilot” studies lacking sufficient power or controls to be conclusive. Therefore, we will limit our focus in this review to findings that have achieved a critical mass of published data and which may be of interest to the psychiatric community. On the biochemical side, we will summarize the changes in neurotransmitter function and neuroendocrine status in FMS patients. Thereafter, we will review the data garnered in more “functional” assays, including sleep lab and brain imaging analyses.

Neurotransmitter Function in FMS

Many of the assays developed in previous efforts to dissect the role and relationships of various neurotransmitter systems in human psychiatric disease have been employed toward the study of FMS. While

various publications have examined the potential roles of a number of neurotransmitters in FMS,⁷⁴⁻⁷⁶ most is known about alterations in 5-HT and SP in affected patients. In summary, the available data suggest a potential decrease in serotonergic activity in FMS patients and support an increase in SP as associated with the disease.

Changes in 5-HT

Evidence for involvement of 5-HT in FMS has been reviewed recently by Alnigenis and Barland.⁷⁷ Many of the symptoms of FMS can be hypothesized as being related to alterations in central serotonergic neurotransmission. The relevance of descending serotonergic pathways to chronic pain was elucidated in the previous section. However, serotonin may also mediate the fatigue that is a frequent complaint of patients with FMS through a number of different mechanisms, including the role that 5-HT plays in regulating the hypothalamic-pituitary-adrenal axis.⁷⁸ Sleep disturbances reported by the majority of FMS patients may also implicate 5-HT due to its central role in the regulation of sleep-wake cycles. (Indeed, 5-HT was the first neurotransmitter hypothesized to be involved in FMS for precisely this reason).^{79,80} Finally, the frequent comorbidity of psychiatric conditions such as depression in FMS patients further supports a disturbance in monoamine function.^{81,82}

To confirm an abnormality in 5-HT mediated neurotransmission, levels of 5-HT itself, its precursor tryptophan, and its metabolites 5-HTP and 5-HIAA, have all been measured in various compartments from FMS patients. As only 1-2% of the body's 5-HT is found in the brain (with the rest derived from platelets, mast cells, and enterochromaffin cells of the gastrointestinal tract), the most consistent results of alterations of 5-HT function in FMS are derived from sampling CSF. While 5-HT levels were not measured directly, both Houvenagel et al. and Russell et al. reported decreased levels of 5-HIAA in the CSF of FMS patients versus controls.^{83,84} In the former case, controls included patients with lower back pain, as well as pain-free subjects, with significant separation in both cases. No correlation between degree of pain and 5-HT levels in FMS patients was documented. While a more recent study by Legangneux et al. was only able to replicate this difference in CSF 5-HIAA levels in female FMS patients versus controls, the small number of male subjects within the study precludes drawing any definitive conclusion.⁸⁵

Several studies have examined peripheral 5-HT levels and most studies find lower levels of 5-HT in the serum of FMS patients as compared to normal controls. In one report, the serum and platelet 5-HT levels were demonstrated to correlate.⁷⁶ A significant inverse correlation between

serum 5-HT level and the number of tender points in FMS patients was noted by Hrycaj, who compared FMS patients with RA patients and normal controls.⁸⁶ Similarly, Emberg et al. found lower serum 5-HT levels in FMS patients than in RA patients.⁸⁷ They speculated that the lower serum 5-HT levels were the result of increased platelet activation in FMS patients, leading to release of 5-HT into the plasma fraction of the blood, whereupon some of the 5-HT is sequestered by binding to nociceptors. Indeed, they found that a high plasma-to-serum 5-HT ratio was associated with orofacial pain and anxiety in FMS patients. However, this result and explanation is in conflict with the recent findings of Legangneux et al., who reported higher levels of 5-HT in FMS samples versus controls, despite using platelet rich plasma (PRP) as the source for assay.⁸⁵

The studies described above primarily examined the steady-state aspects of 5-HT metabolism in FMS patients. A recent study focused on the dynamic aspects of 5-HT metabolism in FMS via the tryptophan depletion (TD) paradigm.^{88,89} A total of 17 FMS patients and 17 controls were examined in this double-blind, randomized cross-over study (ie, TD vs. sham-TD). Eleven patients were antidepressant free for a period of more than one year; the remaining six patients were washed off of antidepressants for 7 days (note that this wash off duration may be considered inadequate for a variety of commonly used agents, including amitriptyline and fluoxetine). At three different time points after the actual or sham TD procedure, blood concentrations of 5-HIAA, tryptophan, and kynurenine were assessed in both patients and controls. In addition, patients were asked to rate their pain via a 10cm visual analog scale. At baseline, no significant differences were found in 5-HIAA levels between patients and controls. In controls, these levels decreased significantly (44% of baseline) as a result of TD. However, in patients, two distinct responses were noted. Eleven patients showed decreased 5-HIAA (60.7% of baseline), like the controls. However, in six patients, 5-HIAA levels increased by 203.6%, suggesting that at least a subgroup of patients have altered 5-HT processing. This altered 5-HT processing was not reflected in pain scores and was not a function of age, antidepressant use, or any other parameter that was measured.

The lack of consistency in measurement of compounds related to 5-HT in body fluids is not surprising, since such variability has been observed when attempting to document reduced 5-HT in depression as well, even within the CSF.⁹⁰ In fact, the selective 5-HT reuptake inhibitors (SSRIs), which increase 5-HT centrally, lead to decreased CSF 5-HIAA, presumably because increased 5-HT within synaptic cleft resulted in feedback inhibition.⁹¹ Based on analyses of post-mortem samples of suicide victims, it has been suggested that CSF 5-HIAA is most reflective of 5-HT activity in the prefrontal.⁹²

In contrast to CSF 5-HIAA levels, the measurement of reduced 5-HT uptake by platelets has proven to be a consistent marker for melancholic depression as, to a lesser extent, has the measurement of 5-HT transporter binding.^{81,93} However, the experience to date in FMS patients has not been quite as satisfying. We have not found any published studies examining platelet 5-HT uptake in FMS patients, while multiple attempts to identify changes within the 5-HT transporter by measurement of platelet [³H] imipramine or [³H] paroxetine binding have yielded conflicting results, ranging from higher,⁷⁵ to lower,⁹⁴ to the same,^{85,95} as controls. A genetic study in FMS patients has demonstrated a possible association of the syndrome with a polymorphism in the 5-HT transporter gene regulatory region.⁹⁶ Specifically, FMS patients in this study had a significantly higher distribution of the S/S genotype (homozygotic "short allele," consisting of a 44-basepair insertion in the transcriptional region of the 5-HT transporter gene), which is associated with decreased 5-HT transporter messenger RNA transcription and decreased 5-HT uptake capacity *in vitro*. These patients also had higher mean levels of depression and psychological distress than the controls.

In summary, at best, the body of published data is suggestive of a dysregulation of 5-HT metabolism in a subset of patients with FMS. However, the assays performed of 5-HT levels and/or its precursors and metabolites, as well as platelet [³H] imipramine or paroxetine binding (representing 5-HT reuptake sites), are often variable in their reported results despite the fact the different laboratories were using similar techniques. While it may very well be possible in some cases to reconcile some of the discrepancies, the analogy to depression (which prompted much of this work to begin with) does not provide much comfort of this being the most productive avenue of research. Specifically, while the monoamine hypothesis of depression was suggested over thirty years ago—and despite an extraordinary amount of effort and resources devoted toward collecting data to establish a direct link between neurotransmitter dysregulation and depression—the goal remains elusive. In hindsight, given the complexity of the clinical presentation of depression and the possible effects on neurotransmitter circuitry, it is not surprising that even if a discrete neurotransmitter defect were to exist, it may very well be masked when measured systemically. Arguably, since depression may appear as only one of multiple symptoms within the FMS complex, the task of sorting out cause and effect within a single neurotransmitter system may prove even more formidable than in the depression experience.

Changes in SP

SP is an 11 amino acid neuropeptide thought to be involved in nociception.^{97,98} It is often co-localized with glutamate in both small, thinly

33

Rao, Gendreau,
and Kranzler

myelinated A_{α} and nonmyelinated C -fiber afferents terminating in the dorsal horn of the spinal cord. Direct application of SP to dorsal horn sensory neurons causes slow and prolonged excitation similar to the response elicited by noxious stimuli. It has been suggested that SP acts as a neuromodulator via the NK_1 receptor, sensitizing the neurons to the effects of other excitatory neurotransmitters.⁹⁹ Because of its presumed role in pain transmission, multiple studies have attempted to document changes of SP in chronic pain states.

In contrast to the 5-HT results, the differences described for SP in FMS have been reproduced by multiple groups. While SP levels in serum and urine of FMS have been reported as normal,⁷³ levels of SP in the CNS have been found to be consistently high in four different studies.^{76,100-102} In all of the above, the SP elevation in CSF was two- to three-fold than that of normals, with little overlap between the values of the two groups.

However, the significance of these results and their relationship to FMS pathophysiology remains unclear. Russell suggests that a trend exists toward correlation of CSF SP levels and pain severity in FMS patients over time.⁷⁴ The source of the increased SP levels is unknown. While it would be anticipated that CSF SP would derive primarily from diffusion of neuropeptides released by afferent nerve fibers into the dorsal horn,¹⁰³ no increase in lumbar-level CSF SP could be induced by noxious pressure on the lower body tender points, which would be expected to stimulate the primary afferents.⁷⁶ This result is inconsistent with extensive animal work that demonstrates release of SP into the dorsal horn in response to noxious stimuli,¹⁰⁴⁻¹⁰⁶ and therefore bears repetition. Significant concentration of both SP and NK_1 receptors are found in other areas of the brain, including the striatum, hippocampus, raphe nucleus, and the lateral nucleus of the hypothalamus.¹⁰⁷ However, it is difficult to attribute, directly or indirectly, the increased CSF levels of SP to increased supraspinal levels.¹⁰⁸⁻¹¹⁰

It is of interest that while high CSF levels of SP have been reported in trigeminal neuralgia¹¹⁰ and chronic daily headache,¹¹² other chronic pain states, including low back pain and painful diabetic neuropathy, are accompanied by low levels of CSF SP and/or monoamines including 5-HT.¹¹³⁻¹¹⁵ Clearly, proposing a one-fit model, such as "wind-up," to all chronic pain disorders is too simplistic to explain the full complement of data collected to date. Nevertheless, as the single most concrete neurochemical difference identified to this point in FMS patients, the high CSF concentrations of SP must be taken into account in any future investigation of mechanisms underlying FMS. Moreover, the potential inverse relationship between 5-HT and SP should be explored further. In this regard, Schwarz et al. reported a clearer result in serum, where, despite normal levels of SP and 5-HT, a strong negative correlation

could be documented between SP and the 5-HT precursor and metabolite, tryptophan and 5-HIAA, respectively.¹¹⁶ Furthermore, in these experiments, high serum 5-HIAA and tryptophan levels showed a significant relation to low pain scores while high 5-HIAA levels were related to good sleep quality and high SP levels to sleep disturbance.

Neuroendocrine Changes

A variety of neuroendocrine alterations have been proposed to underlie the pathophysiology of FMS.³⁸ The rationale behind such proposals is that certain endocrinological conditions—particularly hypocortisolemia, hypothyroidism, and growth hormone (GH) deficiency—have symptoms that strongly resemble those of FMS. While these conditions are generally characterized by hypothalamic hypoactivation, FMS may also be framed as a stress-related disorder. Conceptually, such a state should be associated with hypercortisolemia due to increased hypothalamic-pituitary adrenal axis activation. Several excellent reviews specifically addressing neuroendocrinological perturbations in FMS have recently been published,^{117–119} as summarized below.

It is widely accepted that the hypothalamic-pituitary adrenal (HPA) axis serves as the link between a stressor, such as pain, and the individual's endocrine, autonomic, and behavioral response.¹²⁰ Classically, the HPA axis is regarded as a system programmed to react to changes in the environment by producing chemical messengers that mediate physiological changes to maintain homeostasis.^{119,121} However, recent evidence complicates this simple model by suggesting genetic influences, environmental factors early in life, and exposure to chronic stress can permanently affect the HPA axis and predispose to the development of disease.¹²² While much of this work has been done in the context of understanding the contribution of these changes to the pathophysiology of affective disorders,^{121,122–124} similar mechanisms may be operative in FMS.¹²⁵

The key mediator in the HPA cascade is corticotrophin-releasing factor (CRF), a neuropeptide produced in the paraventricular hypothalamus in response to physical or psychological stress. CRF in turn stimulates the release of corticotropin (ACTH) from anterior pituitary cells, prompting the secretion of glucocorticoids from the adrenal gland to elicit adaptive reactions to the perceived threat, such as increasing blood glucose levels.^{119,125} CRF can also exert secondary inhibitory effects on growth hormone and thyroid-stimulating hormone (TSH) by increasing the secretion of somatostatin from hypothalamic and cortical neurons¹²⁶ and inhibiting hypothalamic LHRH release.¹²⁷ Simultaneous to activation of the HPA axis, an organism will react to stress with a "fight or flight" response mediated by the autonomic nervous system and resulting in physiologic changes such as tachycardia and hypertension.

HPA axis function can be experimentally assessed through two broad strategies: assessment of basal function in the absence of specific stressors and assessment of dynamic responsiveness. Overall basal HPA axis function has been investigated in FMS patients through several approaches. Of note, two studies directly measuring serum cortisol levels, sampled every 10–20 minutes over 24–40 hours, revealed no differences in the phase or amplitudes of cortisol release rhythms between FMS patients and controls.^{128–129} Further, measurements of 24-hour urinary-free cortisol (reflecting integrated 24-hour serum cortisol levels) suggest low to normal cortisol levels in patients vs. controls.^{130–134}

The dynamic responsiveness of the HPA axis in FMS has been assessed using several different types of stressors including exercise, hypoglycemia, IL-6, and exogenous ACTH.¹¹⁸ The exercise studies have been difficult to interpret with different studies implying low, normal, or high HPA axis activity in FMS patients. On the other hand, the studies utilizing hypoglycemia and IL-6 as stressors suggest an impaired ability to increase ACTH (though normal cortisol response) in FMS patients.^{130,135} Furthermore, a blunted cortisol response and exaggerated ACTH response to CRF challenge has been noted.^{133,136,137}

Two other neuroendocrine systems—the hypothalamic-GH axis and the autonomic nervous system—also deserve mention. A number of studies have examined both GH and insulin-like growth factor 1 (IGF-1) dynamics in FMS patients. IGF-1 is a factor produced in the liver, primarily in response to GH secretion; thus, its concentration serves as a proxy for GH release. In general, data support the notion that at least a subset of FMS patients have subnormal GH secretion.¹¹⁸ However, results from a recent study suggest that much of the quantitative differences in GH and IGF-1 levels between FMS patients and controls seen in previous studies may be the result of obesity in the FMS population.¹³⁸ Finally, the autonomic nervous system of FMS patients is characterized by increased sympathetic and decreased parasympathetic tone, as evidenced by exaggerated changes in blood pressure and heart rate with postural change.¹³⁹ There is disagreement, however, as to the interpretation of these findings.

In summary, one interpretation of these data is that FMS is characterized by HPA axis hypoactivation as a result of decreased CRF release. If this hypothesis is true, one can further speculate that the paucity of CRF may contribute to the hyperalgesia in FMS, via CRF's known antinociceptive effects.¹⁴⁰ The dysautonomia in FMS is attributed in this model to lack of stimulatory input by CRF neurons to central control nuclei (A1, A2, A6) within the dorsolateral pons (DLP; see Figure 2) of the sympathetic nervous system¹⁴¹ resulting in relative hypovolemia and exaggerated NE response. Further control of CRF neurons is via stimulatory 5-HT containing neurons projecting from

the midbrain raphe,⁷⁸ stimulatory NE containing neurons from the locus ceruleus,¹⁴² and inhibitory SP containing central neurons.¹⁴³ Therefore, it is tempting to link the hypocortisolism model of FMS to reduced central 5-HT and/or NE, or increased central SP, consistent with Russell's earlier work cited above. Likewise, the observed hypoactivity of the growth hormone (GH) axis in FMS can be attributed to low levels of growth hormone-releasing hormone, that, due to diminished direct stimulation by NE containing neurons, must counterbalance and overcome the tendency of lower levels of CRF to increase somatomedin release.¹³⁵ Whether the characteristic hormonal profile of FMS is involved in the pathophysiology of the disease or is a reflection of the patient's symptoms remains to be determined.

Alterations in Sleep

In addition to pain and fatigue, subjective sleep complaints—particularly nonrestorative sleep—is a common problem in FMS reported to occur in over three-quarters of patients.^{18,144–146} Furthermore, formal sleep electroencephalography has demonstrated a number of abnormalities in the sleep architecture of FMS patients including: prolonged sleep latency; low sleep efficiency; a reduction in slow-wave sleep (SWS); an increase in alpha (stage 1) sleep; and an increased number of awakenings.^{146–150} A fairly common finding in FMS patients is the presence of so-called “alpha-delta” sleep abnormalities—the presence of alpha waves during SWS—which appear to correlate with increased vigilance.^{146,151–153} Other associated sleep problems seen commonly in FMS patients include periodic limb movements and sleep apnea.^{147,154–155}

Sleep abnormalities are, of course, not specific to FMS; they are also seen in other chronic pain conditions^{148,156} and in depression.¹⁵⁷ In fact, it has been shown that sleep deprivation in normal individuals can result in a myalgic syndrome that resembles FMS.^{158–161} This finding has led to the hypothesis that sleep abnormalities may play a causal role in FMS pathophysiology.^{158,161–162}

The initiation and regulation of the sleep state is quite complicated, with a number of mid-brain and pontine serotonergic, NE, and cholinergic nuclei playing a role.¹⁶¹ Thus, it comes as no surprise that agents that affect neurons within these nuclei or neurotransmitter systems may also have profound effects upon sleep. Such agents include antidepressants, benzodiazepines, and γ -OH butyrate; agents which augment SWS may be particularly beneficial.^{157,163} As discussed elsewhere, all three classes of agents have been tested with varying degrees of success in FMS. However, studies correlating drug therapeutic effects with alterations in sleep architecture have been limited and, so far, inconclusive.¹⁶⁴

Neuroimaging Studies

Several studies have utilized functional imaging to investigate abnormalities in CNS function in FMS patients.^{5,10,87,165,166} Two of these^{5,87} used single-photon emission tomography (SPECT) imaging, and one used positron emission tomography (PET).¹⁶⁶ Both of these techniques are similar, employing radioactive tracers to measure regional cerebral blood flow (rCBF) in brain areas of interest. The main difference, at the current state of technology, is that PET uses radioactive tracers with a shorter half-life than SPECT, thus resulting in improved temporal resolution.¹⁶⁷ In contrast, Gracely et al. utilized functional magnetic resonance imaging (fMRI), a technique that directly tracks local changes in blood flow (through changes in water molecule density).^{7,168} Of the three techniques, fMRI has the highest spatial and temporal resolution.¹⁶⁸

A study by Mountz et al. found bilateral hypoperfusion of the thalamus and head of the caudate nucleus in ten women with FMS as compared to seven age and education-matched controls.⁵ Concerns with this study (beyond the small size) were the medication status and the psychological state of the patients. Based on self reports, patients discontinued their medications 4 days prior to the initiation of the study. However, the serum half-lives of some of the medications—including fluoxetine and amitriptyline—are measured in days;^{5,169} thus, significant serum levels of such medications were likely present in some patients at the time of their scans. More significant, however, was the fact that the patient population appeared significantly more depressed and/or anxious (per the Center for Epidemiological Studies Depression Scale (CES-D) and the Trait Anxiety Inventory (TAI), respectively) than the controls.

Some of these concerns are addressed in a more recent SPECT study⁸⁷ aimed at confirming and extending the results of Mountz. This effort evaluated a total of 17 patients and 22 controls (all women). At the time of the study, ten of the FMS patients were taking antidepressants, benzodiazepines, and/or narcotics. The remaining 7 patients were not taking any medications within these classes at the time of the study. Once again, however, the FMS patients were significantly more depressed and/or anxious than were their control counterparts. The results confirmed that rCBF in FMS patients is abnormal; however, statistically significant changes were only found in the right thalamus (the reductions in rCBF seen in the left thalamus did not reach statistical significance). Further, these authors were unable to confirm the bilateral changes in the heads of the caudate nuclei, as found previously by Mountz et al. Finally, additional abnormalities in the inferior pontine tegmentum were noted. The results for patients not taking medications were similar, although less significant; though it is not clear

whether this reduction in significance is a result of differences in neuropharmacology or due to smaller sample sizes.

Taken together, these studies suggest that FMS patients may have reduced rCBF in one or both thalami. Studies in other forms of chronic pain have also found decreases in thalamic rCBF, and these changes may reverse when the pain is alleviated.^{170–173} One concern with both studies is their lack of control for comorbid depression and anxiety. Patients with such conditions, but without FMS, also show abnormalities in regional cerebral blood flow (rCBF), although the overall patterns appear different than those found in the two studies described above.^{174,175} Finally, the possibility of rCBF abnormalities in the inferior pontine tegmentum is tantalizing, as a number of nuclei with descending inhibitory effects on nociception are located in and around this region, as described above (Figure 2).

Of particular interest from a pathophysiological perspective is the work of Gracely et al. who used the fMRI imaging modality to investigate differences in cortical activation between 16 FMS patients and 16 controls while they underwent pressure-pain testing (thumb-nail pressure).⁷ Each FMS subject had an fMRI performed while subjected to “moderately painful” pressure as defined by the Gracely Scale.¹⁷⁶ The control subjects were scanned under two conditions: (a) the “stimulus pressure control” condition and (b) the “subjective pain control” condition. The former referred to testing the controls with the same level of mechanical pressure as the FMS patients, while the latter involved scanning the controls when they, like the FMS patients, reported moderate pain. It was found that the levels of cortical activation seen in FMS patients and the controls under the “subjective pain control” condition were similar. However, fMRI scans of control subjects under the “stimulus pressure control” condition showed no significant activation. These results are strongly supportive of alterations in the threshold and gain of the nociceptive system in FMS patients and are consistent with a model of central sensitization. Note that while data regarding the effects of psychological state on fMRI results were not presented, this is less of a concern in fMRI than in PET or SPECT scans, as a change from baseline within the same patient is being measured.

CLINICAL PHARMACOLOGY OF FMS

At the time the preceding review was written, the vast majority of published results from randomized, controlled studies in FMS examined the use of tricyclic antidepressants; other therapeutic approaches generally had relatively limited data to support their usage.³⁸ Further, a large percentage of the existing clinical data was derived from relatively small studies, often with high dropout and placebo response rates.^{177,178} These

trials tended to be of short duration with very limited information regarding the long-term efficacy of any of the agents. As described below recent trials have addressed a number of these criticisms.

Other issues still remain, however. While the 1990 ACR criteria for the classification of FMS have helped standardize the identification of patients appropriate for entry into clinical trials,^{3,179} the group remains extremely diverse and heterogeneous. The issue of co-morbid depression and its impact on patients' responses to therapeutic interventions is also critical in the design of FMS trials, as will be expanded upon below. Standard practice has been to exclude patients with "severe" psychiatric illness from clinical trials, by incorporating cut-off criteria when using standard psychometric instruments such as the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), or the Beck Depression Inventory (BDI) as prescreening tools.¹¹⁸⁰⁻¹⁸⁴ However, a great deal more information is required before the complex inter-relationships between depression, pain, and other symptoms of FMS can be ascertained.

40

Rao, Gendreau,
and Kranzler

The FMS Pharmacopeia

A wide variety of approaches—both pharmacological and nonpharmacological—have been applied, with varying degrees of success, towards the treatment of the symptoms of FMS. At the present time, the management of fibromyalgia patients involves a complex interplay between the pharmacological management of pain and associated symptoms and the use of non-pharmacological modalities. As the elimination of all FMS symptoms is not currently possible (ie, a cure), the philosophy of management is symptom palliation and functional restoration. The presentation of fibromyalgia symptomatology is highly variable and each patient must have an individualized evaluation before deciding upon an initial treatment plan.¹⁸⁵ Regular follow-up and modification of the initial management strategy is usually required, depending upon the patient's response.

Pharmacological Treatment Strategies

Several recent publications have reviewed the current state of FMS therapy; the data from randomized, double-blind, placebo- or active-controlled trials are summarized in Table 1.^{178,186-192} In this section, we have chosen to briefly review a number of the many agents that have been employed to treat FMS. A drug was included in the summary if it met one or more of the following criteria:

1. A large quantity of clinical data in FMS patients exists, eg TCAs, SSRIs, DRIs, pregabalin, and 5HT₃ receptor antagonists.

TABLE 1

FIBROMYALGIA PHARMACOTHERAPY: SUMMARY OF RANDOMIZED, CONTROLLED TRIALS

CLASS	COMPOUND(S)	PHARMACOLOGY	TREATING FIBROMYALGIA SYMPTOMS ¹			
			PAIN	SLEEP	FATIGUE	MOOD
Tricyclic antidepressants	Amitriptyline	5-HT/NE uptake blocker	+	+	+	+/-
	Clomipramine	Cation channel blocker				
	Doxepin	NMDA antagonist				
		Anticholinergic				
5-HT uptake inhibitors	Fluoxetine	Antihistaminergic				
		5-HT uptake blocker	+/-	+	+/-	+
	Citalopram	5-HT uptake blocker	-	-	-	+
	Sertaline	5-HT uptake blocker	+	+	+	
Dual uptake inhibitors	Paroxetine	5-HT uptake blocker	+	+	-	+
	Venlafaxine	5-HT > NE uptake blocker	-	-	-	-
	Milnacipran	NE > 5-HT uptake blocker	+	-	+	+
		NMDA antagonist				
MAO inhibitors	Duloxetine	5-HT > NE uptake blocker	+	-		+
	Moclobemide	Reversible, MAO-A Inhibitor	-	-	-	-
	Pirlindole	Reversible, MAO-A Inhibitor	+	+	+	+
NSAIDs	Ibuprofen	Nonspecific COX inhibitor	-	-	-	-
	Naproxen					
Antiepileptics	Pregabalin	Ca++ channel blocker	+	+	+	
Sedative/hypnotics	Zopiclone	BZ receptor agonist	-	+	-	-
	Zolpidem					
Muscle relaxants	γ -OH-butyrate	unknown	+	+	+	
	Cyclobenzaprine	5-HT ₂ Antagonist	+	+	+/-	+/-
		Anticholinergic				
Opiates		Antihistaminergic				
	Morphine (IV)	Mu opiate receptor agonist	-			
	Tramadol	Mu agonist	+	-		+
Other		5-HT/NE uptake blocker				
	Tropisetron	5-HT ₃ Antagonist	+	+	+	+
	Ketamine	NMDA Antagonist	+			
	Dextromethorphan					
	CJ-119794	NK ₁ Antagonist	-	-		-
	Growth Hormone	Growth Hormone	+	+	+	

¹ + = beneficial; - = no benefit or detrimental; blank = not tested.

Rao, Gendreau, and Kranzler. *Psychopharmacology Bulletin*. Vol. 40. No. 4. 2007.

41

Rao, Gendreau,
and Kranzler

- The clinical investigation of the drug has been based on solid pre-clinical scientific data, eg, NK₁ antagonists, NMDA antagonists, and GH.
- The drugs have other psychiatric indications, eg, "mood stabilizers" or anti-epileptic drugs (AEDs), atypical anti-depressants, anxiolytics, hypnotics, and α_2 adrenergic agonists, acting as anti-spasticity agents, such as clonidine and tizanidine.

Some of these drugs can be supported as primary therapy. Others may have an adjuvant role addressing symptoms other than pain and important in the overall management of these patients.

Antidepressants

The majority of FMS clinical trials have involved antidepressants of one class or another, as is evident from Table 1. Trials studying the oldest class of agents, tricyclic antidepressants are abundant, though most recent studies have focused on selective serotonin reuptake inhibitors and “atypical antidepressants”—a class that includes dual reuptake inhibitors and monoamine oxidase inhibitors. Despite the multiplicity of antidepressant classes, practically all of the agents currently in clinical use either directly or indirectly increase neurotransmission mediated by the monoamine neurotransmitters, particularly serotonin (5-HT) and/or norepinephrine (NE; also called noradrenaline).¹⁹³ These activities are thought to underlie the antidepressant activity of these compounds, though the exact mechanism by which this occurs is unknown. These pharmacological activities also appear to be an important mechanism by which antidepressant compounds effect centrally-mediated analgesia.¹⁹³

Excepting TCAs, current classification schemes have tended to segregate agents based on their in vitro effects upon 5-HT and NE re-uptake activity. As shown in Table 2, specific agents within a given class vary significantly in terms of their relative actions on the reuptake of these two monoamines or upon binding to their respective transporters.^{194–199} Note, however, that the effects of these agents in vivo may differ significantly from those observed in vitro. For example, despite its low affinity for the NE transporter, venlafaxine has been shown to have in vivo effects consistent with NE reuptake blockade, particularly at higher doses.^{200–202} Conversely, despite the marked difference in relative affinities for the NE and 5-HT transporters that paroxetine displays in vitro, recent data suggests that this agent may possess dual reuptake inhibitory activity in vivo at clinically relevant doses.²⁰³

Tricyclic Antidepressants (TCAs)

TCAs—particularly amitriptyline and doxepin—are widely employed in the treatment of FMS and other chronic pain conditions. (Cyclobenzaprine is also widely used in the treatment of FMS and is structurally very similar to amitriptyline. However, cyclobenzaprine is typically classified as a muscle relaxant rather than an antidepressant and will be discussed below.)^{186–188} Multiple studies support the use of TCAs for the treatment of FMS. Members of this class have frequently been used as the positive controls to which newer agents have been

TABLE 2

COMPARISON OF IN VITRO MONOAMINE UPTAKE INHIBITORY ACTIVITY OR TRANSPORTER BINDING

CLASS	AGENT	NE (NM)	5-HT (NM)	TYPE OF DATA	SELECTIVITY	REFERENCE
					RATIO (NE:5-HT)	
TCA	Amitriptyline	19	2.8	Ki*, transporter binding	7:1	Owens, M., et al., 1997
		35	4.3	KD, transporter binding	8:1	Tatsumi, M., et al., 1997
		24	39	IC50, uptake inhibition	1:1.6	Hyttel, J., 1994
		63	67	Ki, uptake inhibition	1:1.1	Vaishnavi, S.N., (In Press)
	Nortriptyline	1.8	15	Ki*, transporter binding	1:8	Owens, M., et al., 1997
		4.37	18	KD, transporter binding	1:4	Tatsumi, M., et al., 1997
		3.4	570	IC50, uptake inhibition	1:168	Hyttel, J., 1994
	Maprotiline	11.1	5800	KD, transporter binding	1:523	Tatsumi, M., et al., 1997
	Doxepin	29.5	68	KD, transporter binding	1:2.3	Tatsumi, M., et al., 1997
	Dothiepin	46	8.6	KD, transporter binding	5.3:1	Tatsumi, M., et al., 1997
	Imipramine	20	1.3	Ki*, transporter binding	15:1	Owens, M., et al., 1997
		37	1.4	KD, transporter binding	26:1	Tatsumi, M., et al., 1997
		777	0.9	Ki*, transporter binding	863:1	Owens, M., et al., 1997
SSRI	Fluoxetine	240	0.81	KD, transporter binding	296:1	Tatsumi, M., et al., 1997
		7865	1.5	Ki*, transporter binding	5243:1	Owens, M., et al., 1997
	Citalopram	4070	1.16	KD, transporter binding	3509:1	Tatsumi, M., et al., 1997
		85	0.065	Ki*, transporter binding	1307:1	Owens, M., et al., 1997
	Paroxetine	40	0.13	KD, transporter binding	308:1	Tatsumi, M., et al., 1997
		817	0.15	Ki*, transporter binding	5447:1	Owens, M., et al., 1997
	Sertraline	420	0.29	KD, transporter binding	1448:1	Tatsumi, M., et al., 1997
		4.3	14	IC50, uptake inhibition	1:3.3	Rao, S.G., 2002
DRI	Milnacipran	68	151	Ki, uptake inhibition	1:2.2	Vaishnavi, S.N., (In Press)
		100	203	IC50, uptake inhibition	1:2	Moret, C., et al., 1985
		3.45	0.8	IC50, uptake inhibition	4.3:1	Rao, S.G., 2002
	Duloxetine	20	3.7	Ki, uptake inhibition	5.4:1	Vaishnavi, S.N., (In Press)
		2269	7.5	Ki*, transporter binding	300:1	Owens, M., et al., 1997
		1060	8.9	KD, transporter binding	120:1	Tatsumi, M., et al., 1997
	Venlafaxine	1420	145	Ki, uptake inhibition	9.8:1	Vaishnavi, S.N., (In Press)
		1260	74	Ki#, transporter binding	17:1	Beique, J., et al., 1998

*compared to [3H]citalopram or [3H]nisoxetine in HEK-293 cells transfected with human SERT or NET.

*compared to [3H]cyanoimipramine and [3H]nisoxetin in rat brain membranes.

Rao, Gendreau, and Kranzler. *Psychopharmacology Bulletin*. Vol. 40. No. 4. 2007.

compared.^{204–208} The results from TCA trials in FMS have been compiled and analyzed in two meta-analyses by Arnold et al.¹⁷⁶ and O'Malley et al.¹⁸⁸ In essence, the authors both conclude that TCAs provide “moderate” improvement in FMS, with the greatest impact on measurements of sleep, overall well-being, and pain severity. More specifically, Arnold et al. report significant clinical response to TCAs was observed in 25–37% of patients, whereas O'Malley et al. report patients receiving TCAs “four times as likely” to report overall improvement (compared to placebo) and experience moderate reductions in individual symptoms.

Pharmacologically, most TCAs block the reuptake of both 5-HT and/or NE, with varying degrees of relative activities (Table 2). However, amitriptyline, nortriptyline, and dexopin all preferentially block the reuptake of NE with greater potency than that of 5-HT, with selectivity ratios (relative ability to block NE versus 5-HT uptake) ranging from 1.1 for amitriptyline to 168 for nortriptyline. Amitriptyline (with a half-life of 12–36 hours) is metabolized primarily to nortriptyline (with a half-life of 22–88 hours),¹⁶⁹ further adding to the NE bias of amitriptyline especially at the lower dosages which have been historically used to treat chronic pain. The general efficacy of TCAs in treating the pain of FMS, therefore, can be interpreted to support the primacy of NE agonism for analgesic activity. Beyond increasing NE and 5-HT levels, TCAs have other important pharmacologic properties, including dopamine reuptake inhibition, NMDA antagonism, and ion-channel blocking activity.^{209–216} Therefore, there is overlap between the mechanisms of action of the tricyclics and other agents, such as anti-epileptic agents (ie, ion-channel blockade). TCAs additional anti-cholinergic, anti-histaminergic, and α -adrenergic receptor blockade activities impart a wide assortment of undesirable side effects, which often compromise the tolerability and clinical acceptance of this class.²¹⁷

Somewhat ironically, the data supporting the use of TCAs in treating depressed mood in the context of FMS or other pain states is limited, perhaps as a result of most trials evaluating sub-antidepressant doses of TCAs.^{38,187} In most forms of major depressive disorder, however, the efficacy and remission rates of TCAs are equal or superior to those of other classes of agents, an effect hypothesized to result from their effects on both the serotonergic and noradrenergic systems.²¹⁸

Although the anti-depressant activity of these agents may contribute to the efficiency seen in certain patients, their role as centrally-acting analgesics appears to be more critical. This premise is supported by results from trials of various SSRIs, which, in general, do not appear to be as effective analgesics as TCAs even at anti-depressant doses (see below).

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs have revolutionized the field of psychiatry, providing safe and effective treatment of common psychiatric conditions including major depressive disorder, anxiety, and social phobia. Much of their success is attributable to the fact that SSRIs display improved tolerability compared to TCAs, a result of their much higher degree of pharmacological specificity. As implied by their name, SSRIs primarily inhibit the reuptake of 5-HT, and they typically lack the extra-monoaminergic activities which characterize TCAs. The SSRIs fluoxetine, citalopram,

sertraline, and paroxetine have each been evaluated in randomized, placebo-controlled trials in FMS.^{219,220} The results of these trials have been somewhat inconsistent, leaving some debate regarding the relative efficacy of the SSRIs, especially in comparison to TCAs. Two studies have demonstrated positive efficacy for fluoxetine when compared to either placebo or amitriptyline in treating sleep, pain, fatigue, and depression.^{205,219} However, a third study failed to demonstrate any significant improvement in pain, although mild improvements were noted in sleep and depression.²²¹ Two placebo-controlled trials of citalopram have been performed; the first was convincingly negative, with citalopram failing to demonstrate any improvements in pain, fatigue, sleep, or mood.²²² The second study demonstrated that citalopram significantly improved mood, though other outcome measures did not improve significantly.²²³ One study comparing sertraline to amitriptyline demonstrated that the two compounds were equivalent in producing significant improvements in pain, sleep, and fatigue.²²⁴ Finally, a study comparing paroxetine to amitriptyline concluded that, while both improved the symptoms of pain, sleep, and depression, amitriptyline had a larger, more robust effect.²²⁰ Further, amitriptyline was beneficial for fatigue whereas paroxetine did not improve this symptom. Taken together, SSRIs appear to be effective in treating certain FMS symptoms, particularly mood. However, their effect sizes on pain, sleep, and fatigue appear to be less robust in comparison to amitriptyline and the dual reuptake inhibitors.

These data—particularly those pertaining to citalopram, the most 5-HT-specific of the SSRIs (see Table 2)—suggest that serotonergic activity alone is not sufficient to effect analgesia in the chronic pain setting. In fact, the SSRIs as a class are, generally, less efficacious than the in chronic pain states, based on the evidence assembled to date,^{15,40,90,111,225} although there are some exceptions.^{226,227}

Dual-Reuptake Inhibitors (DRIs) Antidepressants

The term “novel” antidepressant covers a great deal of pharmacological variety, including 5-HT/NE dual reuptake inhibitors (DRIs), NE-specific reuptake inhibitors (NRRIs), 5-HT receptor antagonists, and monoamine-oxidase (MAO) inhibitors, among others.²¹⁷ DRIs are pharmacologically similar to some TCAs in their ability to inhibit the reuptake of both 5-HT and NE, a feature that may improve their analgesic efficacy as reviewed in Rao.¹⁹³ Importantly, DRIs differ from TCAs in being generally devoid of significant activity at other receptor systems, and this selectivity results in diminished side effects and enhanced tolerability.¹⁹³ Venlafaxine is the only DRI currently available within the US and is currently indicated for depression and anxiety. Two open label studies

suggest venlafaxine is useful in treating multiple symptoms of FMS.^{228,229} However, these results were not replicated by a recent randomized placebo controlled trial, in which patients treated with venlafaxine did not show any significant improvements in pain, fatigue, sleep, or mood compared to those on placebo.²³⁰ These results may be explained by dosing, as the study by Dwight et al.²³¹ pushed each patient to their maximally tolerated dose or 375 mg/day (mean 167 mg/day), while a study by Zijlstra et al.²³² had a single drug arm with a dose of 75 mg/day. Data suggests that venlafaxine is primarily a 5-HT reuptake inhibitor at lower doses (ie, <150 mg), with NE effects apparent only at higher doses.^{200, 201} On the other hand, it should be noted that the open-label trial by Sayar et al.²³³ also used a single dose of 75 mg and found it effective against various FMS symptoms.

Milnacipran is a DRI presently available in Japan and parts of Europe for the treatment of depression. This agent is unique among clinically available DRIs in its preferential blockade of NE reuptake over 5-HT (Table 2); additionally, this compound is a low affinity NMDA antagonist.¹⁹⁸ Milnacipran is presently in clinical development for FMS in the US, and the results of a Phase II monotherapy trial were recently announced.²³⁴ Placebo was compared to milnacipran, dosed both once and twice daily (when used as an antidepressant, milnacipran is dosed twice daily). All patients were escalated over a 4-week interval to either the maximum tolerated dose of milnacipran or to a total of 200 mg/day. The total trial duration was 12 weeks, (the primary endpoint was pain) tracked on a near-real-time basis using an electronic diary system. Other symptoms that were followed (some using the diary and others at clinic visits) included patient global impression of change (PGIC), sleep, fatigue, and mood. Ninety patients ultimately completed the trial, 32 in the milnacipran QD arm, 37 in the BID arm, and 21 placebo controls. In summary, 37% of patients taking 100 mg of milnacipran twice daily achieved a 50% reduction in pain compared to only 14% of patients on placebo. Furthermore, milnacipran dosed either once or twice daily, had beneficial effects upon PGIC, fatigue, and mood. Side effects including nausea and headache were mild and generally transient. The subgroup of patients with a diagnosable major depressive episode at the start of the trial bears specific mention. Overall, this group's response to milnacipran was similar to that of non-depressed patients; however, their placebo response rate was 33% compared to 5% in non-depressed patients.

A second dual uptake inhibitor, duloxetine—a DRI that, like venlafaxine, preferentially blocks the reuptake of 5-HT over that of NE—is also in clinical development, and the results of a phase II trial of duloxetine in FMS patients were recently announced.¹⁹² This 12-week

monotherapy study compared duloxetine dosed at 60 mg twice daily (120 mg/day) to placebo. Patients were escalated to the final dose over a 2-week escalation period, which followed a 1-week placebo run-in period. The primary outcome measures were the Fibromyalgia Impact Questionnaire (FIQ) total- and pain-subset scores.^{192,235} Other measures included the PGIC, pain (via the Brief Pain Inventory), SF-36, and Quality of Life in Depression scale. A total of 207 patients completed the trial, 104 and 103 patients in the active and placebo arms, respectively. Overall, duloxetine treatment resulted in a significant improvement in total FIQ scores; however, changes in the FIQ pain score did not reach statistical significance. On the other hand, pain as measured by the Brief Pain Inventory was improved. No beneficial effects of duloxetine were noted on fatigue or sleep; indeed, insomnia was a significant side-effect of drug therapy. However, an improvement in mood was noted, as measured by the SF-36 and the Quality of Life in Depression scale.

Other Novel Antidepressants

Reboxetine, classified as a Norepinephrine Reuptake Inhibitor (NERI) due to its selective inhibition of NE reuptake, is on the market as an anti-depressant in parts of Europe; however, it is currently unavailable within the US. A recent open-label trial of reboxetine in 25 FMS patients suggests this compound may be useful for treating pain and fatigue,²³⁶ though more extensive follow-up studies are needed on this point. Another NRI—atomoxetine—has recently been introduced to the US market for the treatment of attention-deficit hyperactivity disorder (ADHD). No data of the efficacy of this compound in pain are presently available. However, a randomized, double-blind, placebo-controlled trial in patients with chronic low back pain reported maprotiline—a tetracyclic norepinephrine reuptake inhibitor (NARI)—to exhibit significantly greater efficacy than paroxetine at standard doses.²³⁷ A different study, however, found maprotiline to be somewhat less effective than amitriptyline in the treatment of post-herpetic neuralgia.²⁰⁷ Therefore, the results of limited empirical studies as well as scientific considerations lead one to assume that NARIs may exhibit better analgesic efficacy than the SSRIs, yet somewhat less efficacy than the TCAs and SNRIs which influence both monoamines.²³⁸ Obviously, additional studies are required to confirm the role these agents will play in the treatment of chronic pain.

There are no published studies on the analgesic capabilities of nefazodone, a 5-HT_{2A} receptor antagonist as well as a weak dual reuptake inhibitor. Animal studies have suggested that its 5-HT₂ antagonism may be anti-nociceptive, due to increases in 5-HT_{1A} mediated neuro-

transmission. The clinical relevance of this has yet to be determined, especially since a related molecule, trazadone, has failed to exhibit significant analgesic effects when used for various pain conditions, including FMS.²³⁹

Mirtazapine is a potent central α_2 autoreceptor antagonist as well as a 5-HT₂ and 5-HT₃ receptor antagonist with some anecdotal success as an analgesic.²⁴⁰ While no controlled studies have been reported, mirtazapine's α_2 autoreceptor mediated increases in NE (as well as 5-HT_{1A}) neurotransmission and its ability to inhibit 5-HT₃ (discussed below) may impart some anti-nociceptive activity.

Reversible Monoamine Oxidase Inhibitors (RIMAs)

MAOIs increase monoamine levels by blocking their breakdown after release from the neuron, a mechanism distinct from TCAs, SSRIs, and DRIs. Non-enzyme-specific, irreversible, MAOI, such as phenelzine and tranylcypromine, have been on the market in the US for many years as antidepressants, though concerns about potentially fatal interactions with certain foods and medications have limited their widespread usage.³⁸ Moclobemide and pirlindole represent "second generation" agents that show improved specific and reversible binding compared to older compounds. Both of these agents have been approved in Europe as antidepressants, though they are not presently available within the US. Preliminary studies with moclobemide in FMS have failed to demonstrate significant analgesic activity when compared to amitriptyline.²⁰⁶ However, a more recent study has demonstrated the efficacy of this compound in CFS, though effects were primarily limited to fatigue.²⁴¹ The results of a randomized, double-blind, placebo controlled trial of pirlindole in FMS were more promising, with beneficial effects upon sleep, pain, fatigue, and mood.²⁴² It is of interest to note that MAOIs show greater efficacy than TCAs in treating atypical depression, a particular depression subtype which is relatively common in patients with chronic pain conditions.²⁴³

Non-Steroidal Anti-Inflammatory Drugs

Non-steroidal anti-inflammatory drugs (NSAIDs; including COX-2-selective agents) and acetaminophen are used by a large number of FMS patients.²⁴⁴ However, numerous studies have failed to confirm their effectiveness as analgesics in FMS, though there is limited evidence of patients experiencing enhanced analgesia when treated with combinations of NSAIDs and other agents.¹⁸⁸ This phenomenon may be a result of the painful, inflammatory conditions—including OA, rheumatoid arthritis, and lupus—being frequently comorbid with FMS.

Anti-Epileptic Drugs (AEDs)

The similarities between certain pathophysiological and biochemical mechanisms observed in epilepsy and neuropathic pain led to initial investigations of AEDs in chronic pain states.²⁴⁵ Agents such as carbamazepine, lamotrigine, phenytoin, benzodiazepines, and gabapentin have been evaluated in neuropathic pain, and have been shown to have analgesic effects to varying degrees.²⁴⁶ As a result, a number of drugs initially labeled as anti-epileptic agents are used regularly as analgesics.

The majority of AEDs increase the seizure threshold by reducing neuronal excitability through sodium and/or calcium channel blockades; this mechanism of action appears to underlie their analgesic activity as well.²⁴⁶ Agents such as benzodiazepines, tiagabine, valproic acid, and topiramate also enhance GABAergic neurotransmission.²⁴⁷ Therefore, although each specific agents' mechanism of action may differ, AEDs as a class generally reduce excitability, decrease ectopic discharge and reduce neurotransmitter release—effects which have been found to impart varying degrees of anti-nociceptive as well as anti-epileptic activity.

The results of a phase II monotherapy trial investigating the use of pregabalin, an AED presently in clinical development, in the treatment of FMS were recently published.²⁴⁸ Pharmacologically, pregabalin is thought to act by blocking certain calcium channels.²⁴⁹ Three different doses of pregabalin—150, 300, and 450mg/day—were compared to placebo in this 8 week study. A total of 410 patients completed the trial—131, 103, 111, and 99 in the placebo, 150 mg, 300 mg, and 450 mg/day arms, respectively. The primary endpoint was pain, as measured by paper diary. Other endpoints included sleep, fatigue, and PGIC. In summary, 450 mg/day of pregabalin was found to result in a 50% pain reduction in 28.9% of patients, a significant difference vs. placebo (13.2%). In addition, sleep, fatigue, and PGIC measures all improved in patients in the 450 mg/day arm of the trial. Unfortunately, this high dose was also associated with a significant incidence of CNS side effects; dizziness, in particular was a problem in almost half of the patients taking this dose.

Carbamazepine and gabapentin have been approved as first-line therapies for trigeminal neuralgia and painful diabetic neuropathy, respectively, and the effectiveness of gabapentin in diabetic post-herpetic neuralgia has also been demonstrated.^{250,251} Gabapentin is structurally and pharmacology similar to pregabalin; however, the gabapentin's efficacy has not formally been demonstrated in FMS. Other anti-convulsants, such as topiramate and lamotrigine, have received recent attention for their potential efficacy in neuropathic pain conditions.^{238,246,252–254} However, no clinical evaluation of the effectiveness of these AEDs in

FMS has been published, and the discouraging side effect profile of many of these agents has typically deterred their evaluation as front-line therapies.

Anxiolytic and Hypnotic Agents

Benzodiazepines are GABA agonists with analgesic actions in the spinal cord and brainstem of animal models,²⁵⁵ as well as anti-epileptic properties as described above and muscle-relaxant properties as discussed below. While several uncontrolled studies have supported the benefit of clonazepam in neuropathic pain (specifically, trigeminal neuralgia), its use is compromised by side effects such as marked drowsiness or frank sedation.^{256,257} In general, studies with other benzodiazepines in neuropathic pain have tended to be small and uncontrolled with inconsistent results.²⁵⁸ The available data are also limited in FMS, but generally, these agents have been ineffective as analgesics.^{259,260}

A handful of studies have been published on the use of certain non-benzodiazepine hypnotics in FMS, such as zopiclone and zolpidem. These reports have suggested that, while improving patients' subjective sleep complaints, these agents do not improve the pain of FMS.²⁶¹⁻²⁶³

Researchers have attempted to elucidate the relationship between circadian rhythms, melatonin secretion and FMS, but have produced inconsistent results.^{128,129,264-266} Melatonin, available in the US as an unregulated dietary supplement, has been evaluated in one small open label pilot study involving 21 patients with FMS who were each given 3 mg of melatonin nightly for 30 days. While this study suggested possible benefits in sleep and tender point counts, melatonin did not appear to impact patients' overall levels of pain or fatigue.²⁶⁴

Gamma-hydroxybutyrate (GHB, also known as sodium oxybate) is a precursor of GABA with powerful sedative properties indicated for narcolepsy in the US. Of note, this compound has been reported to qualitatively improve sleep by increasing the quantity of slow wave sleep (SWS) and decreasing α -intrusion without significantly changing the quantity of REM sleep.²⁶⁷ GHB was recently shown to be useful in improving fatigue, pain, and sleep architecture in patients with FMS in a pilot (18 patient) randomized, double-blind, placebo-controlled, crossover trial.²⁶⁸ It is important to note, however, that several issues are likely to limit the widespread adoption of this compound. First, this agent is a controlled substance due to its abuse potential. Second, the short half-life of γ -hydroxybutyrate typically requires twice nightly administration, a dosing schedule that is likely to interrupt normal sleep architecture. Finally, the low potency of this compound (6 grams were used per night in the above trial) makes controlled-release dosage forms more difficult, as the drug is most practically formulated as a liquid.

Muscle Relaxants

Cyclobenzaprine is a muscle relaxant originally shown to be of some benefit in the management of fibromyalgia in the mid-1980s.¹⁸⁸ Although typically classified as a muscle relaxant, cyclobenzaprine shares structural and pharmacological similarities with TCAs.¹⁹³ The mechanism of action underlying cyclobenzaprine's muscle relaxing action is unclear, though it may be mediated by blockade of 5-HT₂ receptors.¹⁹³ Data generally support its use in FMS, particularly in treating sleep and pain, and there are some data suggesting synergism when cyclobenzaprine is used with fluoxetine.^{188,269} The major problems patients report with cyclobenzaprine are morning "hangover" and dry mouth. These issues may be alleviated to some degree by the use of lower doses of cyclobenzaprine (1 mg to 4 mg) which have recently been shown to improve pain, sleep, and fatigue in FMS patients.²⁷⁰

Tizanidine, an α_2 adrenergic agonist, reduces muscle spasticity by increasing presynaptic inhibition of motor neurons, and has also demonstrated analgesic effects in animal pain models.^{271,272} The anti-nociceptive properties of the α_2 agonists are not surprising when one considers the multiple sites of α_2 adrenergic receptors within both the ascending and descending pathways. For instance, α_2 stimulation reduces activation of PAF terminals, thereby reducing Glu and SP release. Increased α_2 stimulation within the RVM may also activate the descending 5-HT system, providing further anti-nociception. These agents may also directly inhibit dorsal horn projection neurons. A recent 8-week, open-label study of 25 fibromyalgia patients receiving a total daily dose of tizanidine of 4–24 mg reported significant improvements in several parameters, including sleep, pain, and measures of quality of life.²⁷³ Of particular interest is the demonstration that treatment with tizanidine results in a reduction in substance P (SP) levels within the cerebrospinal fluid (CSF) of patients with FMS.

Baclofen is a GABAB agonist also approved as an anti-spasticity agent and likewise documented to be an effective adjuvant analgesic in the management of various types of neuropathic pain.^{274–276} While its mode of action is not fully characterized, its analgesic effects may be due to suppression of dorsal horn neuronal activity. There are currently no data pertaining to the use of baclofen in patients with FMS.

Opiates

Typical opiate agonists such as morphine act at various combinations of the mu, delta, and kappa opiate receptors. These receptors are located throughout the CNS with all three receptors appearing to play a role in analgesia.¹⁹³ A recent study reported reduced levels of b-endorphin in peripheral blood mononuclear cells of fibromyalgia patients, implicating

the possibility of a suboptimal endogenous in fibromyalgia patients.²⁷⁷ Morphine and morphine-like compounds are widely used in many chronic pain states, including TMJD²⁷⁸ and subsets of CLBP.²⁷⁴ A survey of academic medical centers in the US reported that opiates were used in about 14% of FMS (mainly tertiary care) patients.²⁴⁴

There have been only a few controlled clinical trials of these agents in FMS. Interestingly, acutely administered intravenous morphine was not found to be effective in treating FMS pain.²⁸⁰ Tramadol is another widely used analgesic that has a unique mechanism of action involving weak mu agonist activity combined with 5-HT/NE reuptake inhibition.¹⁸⁷ Three double-blind studies have demonstrated the efficacy and tolerability of tramadol in the management of fibromyalgia pain, as an isolated compound^{281,282} and in fixed-dose combination with acetaminophen (ie, "Ultracet").²⁷⁸

Miscellaneous Agents

5-T₃ receptor antagonists (such as ondansetron and tropisetron), which are best known for their anti-emetic properties, also have analgesic effects.²⁸⁴ Animal models have demonstrated that blockade of 5-HT₃ receptors has both nociceptive and anti-nociceptive effects, and clinical trials in settings of chronic pain have repeatedly revealed a bell-shaped dose response curve, suggesting that optimal analgesic effect may involve a dose-dependent balancing act between these opposing activities. This duality of effect may be due in part to the presence of 5-HT₃ receptors on both PAF terminals and inhibitory dorsal horn interneurons.²⁸⁴⁻²⁸⁷ This is an appropriate reminder of the complex nature by which the myriad 5-HT (and other) receptors interact throughout the pain pathways.

Members of the German Fibromyalgia Study Group extensively studied tropisetron in patients with FMS.²⁸⁸⁻²⁹² In addition to several small, open-label evaluations, a single randomized placebo-controlled double-blind trial investigated the effectiveness of 5 mg, 10 mg, or 15 mg tropisetron given once daily for 10 days to 418 FMS patients. The results from this study suggest modest but statistically and clinically significant reductions in pain, but only in those patients treated with 5 mg tropisetron, consistent with the earlier described bell-shaped dose response curve. Constipation and other GI complaints were commonly reported, as is common with other 5-HT₃ blockers.

As mentioned above, certain TCAs are known to be NMDA receptor antagonists, though their activity in this regard is relatively weak (ie, they are low affinity agents).¹⁹³ Three studies have demonstrated high-level NMDA receptor blockades (imparted by the use of high affinity agents or large doses of low affinity compounds) can improve pain symptoms in

FMS patients.^{280,294,295} However, such high-level blockades are associated with significant cognitive side-effects, thus potentially limiting the utility of this approach. While the search continues for agents with more tolerable side effect profiles, NMDA receptor antagonists may ultimately prove to be most beneficial as adjunctive therapies when used concomitantly with other analgesics.²⁹⁰

Considering the observation that SP levels within the CSF of patients with FMS are routinely elevated, drugs designed specifically as SP or NK₁ receptor antagonists are theoretically attractive. Indeed, a double-blind, placebo-controlled, randomized 8-week crossover study was conducted in 1994 to evaluate the use of a selective NK₁ antagonist, CJ-119794, in the treatment of FMS.²⁹⁶ In short, the results were disappointing; treatment with CJ-119794 resulted in no significant improvements in pain, sleep, or affective endpoints. Unfortunately, this result is rather consistent with NK₁ antagonists in a variety of clinical settings, despite promising preclinical results.⁹⁷ The only notable exception to this general trend has been within the antiemetic indication, for which anipretant—also known as MK-0869—has recently received approval in the US.

Bennett et al. conducted a randomized, placebo-controlled, double-blind study of the clinical effects of growth hormone (GH) therapy in 50 women with FMS and pre-determined low IGF-1 levels.²⁹⁷ Patients were randomized to self-inject daily either GH or placebo (reconstituted excipient only) for 9 months. The dose of GH was adjusted to maintain blood IGF-1 levels at approximately 250 mg/ml. The GH-treated group achieved a significant improvement in pain, sleep, and fatigue scores at 9 months compared to baseline, whereas no significant improvement was observed in the placebo group. Patients' responses tended to lag behind the initiation of GH therapy by approximately 6 months, although measurable improvements in muscle strength and exercise performance were discernible after 3 months with progressive improvement thereafter. Since GH is known to raise energy levels, increase exercise capacity, build muscle strength, and improve cognitive function in other patient groups with decreased basal GH levels,^{298–301} the improvements seen in this trial may merely reflect the general metabolic effects of GH and not be representative of a syndrome-specific response. Moreover, while GH therapy would appear to offer this subgroup of patients some symptomatic improvement, financial considerations limit the viability of GH as a long-term therapy in this population.

Non-Pharmacological Treatment Strategies

The two best studied non-pharmacological therapies are cognitive behavioral therapy (CBT) and exercise. Both of these therapies have

been shown to be efficacious in the treatment of FMS, and excellent reviews of these treatments are referenced.^{27,46,302} Both of these treatments can lead to sustained (eg, greater than one year) improvements and are very effective in compliant individuals. The challenge for new studies examining these treatments is to improve long-term adherence and compliance, and to move toward using modalities such as the Internet, or telemedicine, that will allow a larger number of patients access to these therapies. Also, new studies need to address the optimal manner in which to combine pharmacologic and non-pharmacologic therapies.

DISCUSSION

The FMS landscape has changed markedly over the past 2 years since the preceding review was written.³⁸ In summary, FMS has moved much closer to the mainstream, gaining authenticity in many circles as a legitimate, treatable condition. Such a vast change in attitude would have been inconceivable just a few short years ago. The next few years promise to be equally exciting, as FMS garners more research interest and as drugs specifically indicated for FMS enter the market.


In the preceding review, we presented a conceptual view of FMS that attempted to integrate the various clinical and laboratory findings seen in FMS patients (Figure 4).³⁸ To summarize, we proposed that in susceptible individuals, all of the symptoms and findings are reciprocally interconnected, and abnormalities in one element would ultimately result in perturbations in the others. Equally important is the fact that no distinctions were made nor hierarchy presumed between the primary insult and secondary symptoms. From a therapeutic perspective, this model has an important implication: an attempt to treat a single symptom in isolation will not be effective in treating the syndrome. We suggest that trial data for zopiclone and amitriptyline support this hypothesis. The former compound is a sedative/hypnotic with no demonstrable efficacy against affective disorders, pain, etc. As predicted by the model, zopiclone's therapeutic benefits are limited to sleep in FMS patients. Amitriptyline, on the other hand, can theoretically benefit all of the elements in Figure 4, and this agent's global effectiveness is borne out by trial data.

Based upon this model and available clinical trial data, we predict that three pharmacological classes of drugs likely to be of benefit to patients with FMS:

- Dual reuptake inhibitors
- Antiepileptic compounds
- NK₁ antagonists

FIGURE 4

A MODEL OF FIBROMYALGIA AS A BIDIRECTIONAL CYCLE



Rao, Gendreau, and Kranzler. *Psychopharmacology Bulletin*. Vol. 40. No. 4. 2007.

On the first two points, our predictions have been born out experimentally. Both milnacipran and duloxetine have demonstrated efficacy in FMS, and venlafaxine may be beneficial at higher doses.^{192,228,234} Of note, the ranking of these compounds in order of decreasing efficacy—milnacipran, duloxetine, and venlafaxine—also corresponds to their relative activities on NE vs. 5-HT; a point that confirms the importance of NE to analgesia. Also of note is the marked dissociation in placebo (but not active) response rates seen in milnacipran trials; data which support the notion of pathophysiology underlying pain and depression are different.³⁰³

Pregabalin appears to be a very effective compound in the treatment of FMS, based upon the one of the largest double-blind, placebo-controlled, randomized trial performed in FMS to date. The major concern with respect to this compound is tolerability as CNS side effects were extremely prevalent at the dose required for a statistically significant result. It should be noted, however, that the data to date regarding pregabalin in FMS come from a monotherapy trial. One may speculate that a lower, more tolerable dose would be equally efficacious if combined with another effective drug, such as a DRI. Indeed, such a combination may be ideal, as the DRIs tend to cause a degree of insomnia; pregabalin dosed at night would, presumably, counteract this side effect.

We recognized in the previous review that our prediction regarding the efficacy of NK₁ antagonists in FMS was speculative.³⁸ In light of the

generally poor clinical showing of this class of agents in general, perhaps the negative results seen with CJ-11974 in FMS are not surprising.²⁹¹ However, it may still be too early to condemn the entire class as issues with blood brain barrier penetration, affinity to human NK₁ receptors, etc. have been noted with several early compounds.

It is important to note that none of the compounds presently in active development for FMS are considered traditional analgesics or anti-inflammatories; all of them are thought to have their primary effects almost exclusively within the CNS. Thus, we hope this review will stimulate dialogue between the community of physicians who treat FMS patients and the scientific and clinical researchers studying brain physiology and pharmacology. Some of the ideas resulting from that dialogue will undoubtedly involve the use of pharmacologically active agents to further dissect the biology of FMS and/or determine clinical response. We expect our understanding of FMS, as well as the physiological links between mind and body in the "functional somatic disorders" in general, will advance rapidly as a result of such collaborative efforts.

56

Rao, Gendreau,
and Kranzler

DISCLOSURE

Dr. Rao, Dr. Gendreau, and Dr. Kranzler are all employees of Cypress Biosciences, Inc. ♣

REFERENCES

1. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. *Curr Pain Headache Rep.* 2001;5(4):320-9.
2. Gran JT. The epidemiology of chronic generalized musculoskeletal pain. *Best Pract Res Clin Rheumatol.* 2003;17(4):547-61.
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum.* 1990;33(2):160-72.
4. Daoud KF, Barkhuizen A. Rheumatic mimics and selected triggers of fibromyalgia. *Curr Pain Headache Rep.* 2002;6(4):284-8.
5. Mountz JM, Bradley LA, Modell JG, et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. *Arthritis & Rheumatism.* 1995;38(7):926-38.
6. Arroyo JF, Cohen ML. Abnormal responses to electrocutaneous stimulation in fibromyalgia. *J Rheumatol.* 1993;20(11):1925-31.
7. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. PG-1333-43. *Arthritis Rheum.* 2002;46(5).
8. Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. *Arthritis Rheum.* 2003;48(5):1420-9.
9. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. *Pain.* 2003;105(3):403-13.
10. Gracely RH, Grant MA, Giesecke T. Evoked pain measures in fibromyalgia. *Best Pract Res Clin Rheumatol.* 2003;17(4):593-609.
11. Staud R, Smithman ML. Peripheral and central sensitization in fibromyalgia: pathogenetic role. *Curr Pain Headache Rep.* 2002;6(4):259-66.
12. Olsen NJ, Park JH. Skeletal muscle abnormalities in patients with fibromyalgia. *Am J Med Sci.* 1998;315(6):351-8.
13. Simms RW, Roy SH, Hrovat M, et al. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism [see comments]. *Arthritis & Rheumatism.* 1994;37(6):794-800.

14. Simms RW. Fibromyalgia is not a muscle disorder. *Am J Med Sci.* 1998;315(6):346-50.
15. Sprott H, Bradley LA, Oh SJ, et al. Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. *Arthritis Rheum.* 1998;41(9):1689-94.
16. Ernberg M, Voog U, Alstergren P, Lundeberg T, Kopp S. Plasma and serum serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. *J Orofac Pain.* 2000;14(1):37-46.
17. Nicassio PM, Moxham EG, Schuman CE, Gevirtz RN. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. *Pain.* 2002;100(3):271-9.
18. Moldofsky H. Management of sleep disorders in fibromyalgia. *Rheum Dis Clin North Am.* 2002;28(2):353-65.
19. Park DC, Glass JM, Minear M, Crofford LJ. Cognitive function in fibromyalgia patients. *Arthritis Rheum.* 2001;44(9):2125-33.
20. Katon W, Sullivan M, Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. *Ann Intern Med.* 2001;134(9 Pt 2):917-25.
21. Boissevain MD, McCain GA. Toward an integrated understanding of fibromyalgia syndrome. I. Medical and pathophysiological aspects. *Pain.* 1991;45(3):227-38.
22. Boissevain MD, McCain GA. Toward an integrated understanding of fibromyalgia syndrome. II. Psychological and phenomenological aspects. *Pain.* 1991;45(3):239-48.
23. Hudson JI, Hudson MS, Pliner LF, Goldenberg DL, Pope HG, Jr. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. *Am J Psychiatry.* 1985;142(4):441-6.
24. Hawley DJ, Wolfe F. Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients. *J Rheumatol.* 1991;18(10):1552-7.
25. White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. *Arthritis Rheum.* 1999;42(1):76-83.
26. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. *Ann Intern Med.* 2001;134(9 Pt 2):868-81.
27. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. *Best Pract Res Clin Rheumatol.* 2003;17(4):563-74.
28. Barsky AJ, Borus JF. Functional somatic syndromes. *Ann Intern Med.* 1999;130(11):910-21.
29. Manu P, ed. *Functional Somatic Syndromes: Etiology, Diagnosis, and Treatment.* New York City: Cambridge University Press; 1999.
30. Winfield JB. Does pain in fibromyalgia reflect somatization? *Arthritis Rheum.* 2001;44(4):751-3.
31. 1998 National Ambulatory Medical Care Survey. Princeton, NJ: Covance, Inc.; 1998.
32. Hadler NM. Fibromyalgia, chronic fatigue, and other iatrogenic diagnostic algorithms. Do some labels escalate illness in vulnerable patients? *Postgrad Med.* 1997;102(2):161-2, 165-6, 171-162 passim.
33. Hadler NM. Is fibromyalgia a useful diagnostic label? [see comment]. *Cleve Clin J Med.* 1996;63(2):85-87.
34. Ehrlich GE. Pain is real; fibromyalgia isn't. *J Rheumatol.* 2003;30(8):1666-7.
35. Wolfe F. For example is not evidence: fibromyalgia and the law. *J Rheumatol.* 2000;27(5):1115-6.
36. Quintner JL, Cohen ML. Fibromyalgia falls foul of a fallacy. *Lancet.* 1999;353(9158):1092-4.
37. Cohen ML, Quintner JL. Fibromyalgia syndrome, a problem of tautology. *Lancet.* 1993; 342(8876):906-9.
38. Kranzler J, Gendreau J, Rao S. The Psychopharmacology of Fibromyalgia: A Drug Development Perspective. *Psychopharmacology Bull.* 2002;36(1):165-213.
39. Witter J, Simon LS. Chronic pain and fibromyalgia: the regulatory perspective. *Best Pract Res Clin Rheumatol.* 2003;17(4):541-6.
40. Dionne RA, Witter J. NIH-FDA Analgesic Drug Development Workshop: translating scientific advances into improved pain relief. *Clin J Pain.* 2003;19(3):139-47.
41. Birket-Smith M. Somatization and chronic pain. *Acta Anaesthesiol Scand.* 2001;45(9):1114-20.
42. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. *Arch Gen Psychiatry.* 2003;60(1):39-47.
43. Blackburn-Munro G, Blackburn-Munro RE. Chronic pain, chronic stress and depression: coincidence or consequence? *J Neuroendocrinol.* 2001;13(12):1009-23.
44. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. *N Engl J Med.* 28 1999;341(18):1329-35.
45. Gureje O, Simon GE, Von Korff M. A cross-national study of the course of persistent pain in primary care. *Pain.* 2001;92(1-2):195-200.
46. Williams DA. Psychological and behavioural therapies in fibromyalgia and related syndromes. *Best Pract Res Clin Rheumatol.* 2003;17(4):649-65.

57

Rao, Gendreau,
and Kranzler

47. Bradley LA, Alberts KR. Psychological and behavioral approaches to pain management for patients with rheumatic disease. *Rheum Dis Clin North Am.* 1999;25(1):215-32, viii.
48. Singh BB, Berman BM, Hadhazy VA, Creamer P. A pilot study of cognitive behavioral therapy in fibromyalgia. *Altern Ther Health Med.* 1998;4(2):67-70.
49. Melzack R, Wall PD. Pain mechanisms: a new theory. *Science.* 1965;150(699):971-9.
50. Dickenson AH. Spinal cord pharmacology of pain. *Br J Anaesth.* 1995;75(2):193-200.
51. Jones SL, Gebhart GF. Spinal pathways mediating tonic, coeruleospinal, and raphe-spinal descending inhibition in the rat. *J Neurophysiol.* 1987;58(1):138-59.
52. DeLander GE, Hopkins CJ. Interdependence of spinal adenosinergic, serotonergic and noradrenergic systems mediating antinociception. *Neuropharmacology.* 1987;26(12):1791-4.
53. Llewellyn MB, Azami J, Roberts MH. The effect of modification of 5-hydroxytryptamine function in nucleus raphe magnus on nociceptive threshold. *Brain Res.* 1984;306(1-2):165-70.
54. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. *Annu Rev Neurosci.* 1991;14:219-45.
- 55.Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. *Pain.* 1993;52(3):259-85.
56. Herrero JF, Laird JM, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? *Progress in Neurobiology.* 2000;61(2):169-203.
57. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. *Nature.* 1983;306(5944):686-8.
58. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. *Eur J Pain.* 2000;4(1):5-15.
59. Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in 'wind-up' of class 2 neurones in the dorsal horn of the rat. *Brain Res.* 1987;424(2):402-6.
60. Dickenson AH, Sullivan AF. Electrophysiological studies on the effects of intrathecal morphine on nociceptive neurones in the rat dorsal horn. *Pain.* 1986;24(2):211-22.
61. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. *Trends Pharmacol Sci.* 1990;11(8):307-9.
62. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective [see comments]. *Eur J Pain.* 2000;4(1):5-15.
63. Dougherty PM, Palecek J, Paleckova V, Sorkin LS, Willis WD. The role of NMDA and non-NMDA excitatory amino acid receptors in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal, and electrical stimuli. *J Neurosci.* 1992;12(8):3025-41.
64. Dougherty PM, Willis WD. Enhancement of spinothalamic neuron responses to chemical and mechanical stimuli following combined micro-iontophoretic application of N-methyl-D-aspartic acid and substance P. *Pain.* 1991;47(1):85-93.
65. Dougherty PM, Palecek J, Zorn S, Willis WD. Combined application of excitatory amino acids and substance P produces long-lasting changes in responses of primate spinothalamic tract neurons. *Brain Res Brain Res Rev.* 1993;18(2):227-46.
66. Suzuki R, Hunt SP, Dickenson AH. The coding of noxious mechanical and thermal stimuli of deep dorsal horn neurones is attenuated in NK1 knockout mice. *Neuropharmacology.* 2003;45(8):1093-1100.
67. Jasmin L, Boudah A, Ohara PT. Long-term effects of decreased noradrenergic central nervous system innervation on pain behavior and opioid antinociception. *J Comp Neurol.* 2003;460(1):38-55.
68. Urban MO, Coutinho SV, Gebhart GF. Involvement of excitatory amino acid receptors and nitric oxide in the rostral ventromedial medulla in modulating secondary hyperalgesia produced by mustard oil. *Pain.* 1999;81(1-2):45-55.
69. Kovelowski CJ, Ossipov MH, Sun H, Lai J, Malan TP, Porreca F. Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. *Pain.* 2000;87(3):265-73.
70. Coutinho SV, Urban MO, Gebhart GF. Role of glutamate receptors and nitric oxide in the rostral ventromedial medulla in visceral hyperalgesia. *Pain.* 1998;78(1):59-69.
71. Urban MO, Gebhart GF. Supraspinal contributions to hyperalgesia. *Proc Natl Acad Sci USA.* 1999;96(14):7687-92.
72. Quintero L, Cuesta MC, Silva JA, et al. Repeated swim stress increases pain-induced expression of c-Fos in the rat lumbar cord. *Brain Res.* 2003;965(1-2):259-68.
73. Quintero L, Moreno M, Avila C, Arcaya J, Maixner W, Suarez-Roca H. Long-lasting delayed hyperalgesia after subchronic swim stress. *Pharmacol Biochem Behav.* 2000;67(3):449-58.
74. Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. *Am J Med Sci.* 1998;315(6):377-84.

75. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. *J Rheumatol.* 1992;19(1):104-9.
76. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. *Arthritis Rheum.* 1994;37(11):1593-1601.
77. Alnigenis MN, Barland P. Fibromyalgia syndrome and serotonin. *Clin Exp Rheumatol.* 2001;19(2):205-10.
78. Fuller RW. The involvement of serotonin in regulation of pituitary-adrenocortical function. *Front Neuroendocrinol.* 1992;13(3):250-70.
79. Moldofsky H. Sleep and musculoskeletal pain. *Am J Med.* 1986;81(3A):85-9.
80. Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. *Adv Neurol.* 1982;33:51-7.
81. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. *Clin Chem.* 1994;40(2):288-95.
82. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. *Biol Psychiatry.* 1999;46(9):1219-33.
83. Houvenagel E, Forzy G, Leloire O, et al. [Cerebrospinal fluid monoamines in primary fibromyalgia.] *Rev Rhum Mal Osteoartic.* 1990;57(1):21-3.
84. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. *Arthritis Rheum.* 1992;35(5):550-6.
85. Legangneux E, Mora JJ, Spreux-Varoquaux O, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. *Rheumatol (Oxford).* 2001;40(3):290-6.
86. Hrycaj P, Stratz T, Muller W. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. *J Rheumatol.* 1993;20(11):1986-8.
87. Kwiatek R, Barnden L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. *Arthritis Rheum.* 2000;43(12):2823-33.
88. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. *Biol Psychiatry.* 1999;46(2):212-20.
89. Schwarz MJ, Offenbaecher M, Neumeister A, et al. Evidence for an altered tryptophan metabolism in fibromyalgia. *Neurobiol Dis.* 2002;11(3):434-442.
90. Mann JJ. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. *Neuropsychopharmacol.* 1999;21(2 Suppl):99S-105S.
91. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. *Acta Psychiatr Scand.* 1989;79(6):586-96.
92. Gibbons RD, Davis JM. Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels. *Acta Psychiatr Scand.* 1986;74(1):8-12.
93. Stahl SM, Woo DJ, Mefford IN, Berger PA, Ciaranello RD. Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. *Am J Psychiatry.* 1983;140(1):26-30.
94. Magni G, Andreoli F, Arduino C, et al. [3H] imipramine binding sites are decreased in platelets of chronic pain patients. *Acta Psychiatr Scand.* 1987;75(1):108-10.
95. Kravitz HM, Katz R, Kot E, Helmke N, Fawcett J. Biochemical clues to a fibromyalgia-depression link: imipramine binding in patients with fibromyalgia or depression and in healthy controls. *J Rheumatol.* 1992;19(9):1428-32.
96. Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. *Arthritis Rheum.* 1999;42(11):2482-8.
97. Hill R. NK1 (substance P) receptor antagonists—why are they not analgesic in humans? *Trends Pharmacol Sci.* 2000;21(7):244-6.
98. Hokfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. *J Intern Med.* 2001;249(1):27-40.
99. Dougherty PM, Palecek J, Paleckova V, Willis WD. Infusion of substance P or neurokinin A by microdialysis alters responses of primate spinothalamic tract neurons to cutaneous stimuli and to iontophoretically released excitatory amino acids. *Pain.* 1995;61(3):411-25.
100. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. *Pain.* 1988;32(1):21-6.

101. Welin M, Borge B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in csf from fibromyalgia patients. *J Musculoskeletal Pain*. 1995; 3(suppl1):4.
102. Bradley LE, Alberts KR, Alarcon GS, Alexander MR. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). *Arthritis Rheum*. 1996;39(suppl9):S212.
103. Hornfeldt CS, Sun X, Larson AA. The NH2-terminus of substance P modulates NMDA-induced activity in the mouse spinal cord. *J Neurosci*. 1994;14(5 Pt 2):3364-9.
104. Oku R, Satoh M, Takagi H. Release of substance P from the spinal dorsal horn is enhanced in polyarthritic rats. *Neurosci Lett*. 1987;74(3):315-9.
105. Schaible HG, Jarrott B, Hope PJ, Duggan AW. Release of immunoreactive substance P in the spinal cord during development of acute arthritis in the knee joint of the cat: a study with antibody microprobes. *Brain Res*. 1990;529(1-2):214-23.
106. Duggan AW, Hendry IA, Morton CR, Hutchison WD, Zhao ZQ. Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat. *Brain Res*. 1988;451(1-2):261-73.
107. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. *Physiol Rev*. 1993; 73(2):229-308.
108. Walker PD, Riley LA, Hart RP, Jonakait GM. Serotonin regulation of tachykinin biosynthesis in the rat neostriatum. *Brain Res*. 1991;546(1):33-9.
109. Murphy RM, Zemlan FP. Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. *Psychopharmacol*. 1987;93(1):118-21.
110. Sharma HS, Nyberg F, Olsson Y, Dey PK. Alteration of substance P after trauma to the spinal cord: an experimental study in the rat. *Neuroscience*. 1990;38(1):205-12.
111. Strittmatter M, Grauer M, Isenberg E, et al. Cerebrospinal fluid neuropeptides and monoaminergic transmitters in patients with trigeminal neuralgia. *Headache*. 1997;37(4):211-6.
112. Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P. Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. *Cephalalgia*. 2003;23(3):166-74.
113. Sjostrom S, Tamsen A, Hartvig P, Folkesson R, Terenius L. Cerebrospinal fluid concentrations of substance P and (met)enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. *Anesth Analg*. 1988;67(10):976-81.
114. Tsigos C, Diemel LT, White A, Tomlinson DR, Young RJ. Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. *Clin Sci (Colch)*. 1993;84(3):305-11.
115. Fischer HP, Eich W, Russell IJ. A possible role for saliva as a diagnostic fluid in patients with chronic pain. *Semin Arthritis Rheum*. 1998;27(6):348-59.
116. Schwarz MJ, Spath M, Muller-Bardorff H, Pongratz DE, Bondy B, Ackenheil M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. *Neurosci Lett*. 1999;259(3):196-8.
117. Geenen R, Jacobs JW, Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. *Rheum Dis Clin North Am*. 2002;28(2):389-404.
118. Adler GK, Manfredsdottir VF, Creskoff KW. Neuroendocrine abnormalities in fibromyalgia. *Curr Pain Headache Rep*. 2002;6(4):289-98.
119. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. *J Psychosom Res*. 2002;53(4):865-71.
120. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. *Eur J Pharmacol*. 2003; 463(1-3):235-72.
121. Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. *Ann NY Acad Sci*. 1998;851:311-35.
122. Gutman DA, Nemeroff CB. Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. *Physiol Behav*. 2003;79(3):471-8.
123. Penza KM, Heim C, Nemeroff CB. Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. *Arch Women Ment Health*. 2003;6(1):15-22.
124. Newport DJ, Heim C, Owens MJ, et al. Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. *Neuropsychopharmacology*. 2003;28(3):569-76.
125. Neeck G, Crofford LJ. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. *Rheum Dis Clin North Am*. 2000;26(4):989-1002.
126. Peterfreund RA, Vale WW. Ovine corticotropin-releasing factor stimulates somatostatin secretion from cultured brain cells. *Endocrinol*. 1983;112(4):1275-8.

127. Frias J, Puertas A, Ruiz E, Ortega E. Effect of corticotropin releasing factor (CRF) injected into the median eminence on LH secretion in male rats. *Neurochem Res.* 1997;22(2):171-4.
128. Klerman EB, Goldenberg DL, Brown EN, Maliszewski AM, Adler GK. Circadian rhythms of women with fibromyalgia. *J Clin Endocrinol Metab.* 2001;86(3):1034-9.
129. Korszun A, Sackett-Lundeen L, Papadopoulos E, et al. Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. *J Rheumatol.* 1999;26(12):2675-80.
130. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. *Am J Med.* 1999;106(5):534-43.
131. Maes M, Lin A, Bonaccorso S, et al. Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. *Acta Psychiatr Scand.* 1998;98(4):328-35.
132. Lentjes EG, Griep EN, Boersma JW, Romijn FP, de Kloet ER. Glucocorticoid receptors, fibromyalgia and low back pain. *Psychoneuroendocrinol.* 1997;22(8):603-14.
133. Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. *Arthritis Rheum.* 1994;37(11):1583-92.
134. Crofford LJ. Personal Communication; 2001.
135. Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. *Arthritis Rheum.* 2000;43(4):872-80.
136. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome [see comments]. *J Rheumatol.* 1993;20(3):469-74.
137. Riedel W, Layka H, Neeck G. Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. *Z Rheumatol.* 1998;57(Suppl 2):81-7.
138. McCall-Hosenfeld JS, Goldenberg DL, Hurwitz S, Adler GK. Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia. *J Rheumatol.* 2003;30(4):809-14.
139. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. *Semin Arthritis Rheum.* 2000;29(4):217-27.
140. Sawamura S, Obara M, Takeda K, Maze M, Hanaoka K. Corticotropin-releasing factor mediates the antinociceptive action of nitrous oxide in rats. *Anesthesiol.* 2003;99(3):708-15.
141. Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. *Neuroendocrinol.* 1983;36(3):165-86.
142. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. *Proc Assoc Am Physicians.* 1999;111(1):22-34.
143. Jessop DS, Renshaw D, Larsen PJ, Chowdhury HS, Harbuz MS. Substance P is involved in terminating the hypothalamo-pituitary-adrenal axis response to acute stress through centrally located neurokinin-1 receptors. *Stress.* 2000;3(3):209-20.
144. Smythe HA, Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. *Bull Rheum Dis.* 1977;28(1):928-31.
145. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. *Semin Arthritis Rheum.* 1981;11(1):151-71.
146. Roizenblatt S, Moldofsky H, Benedito-Silva AA, Tufik S. Alpha sleep characteristics in fibromyalgia. *Arthritis Rheum.* 2001;44(1):222-30.
147. Sergi M, Rizzi M, Braghiroli A, et al. Periodic breathing during sleep in patients affected by fibromyalgia syndrome. *Eur Respir J.* 1999;14(1):203-8.
148. Wittig RM, Zorick FJ, Blumer D, Heilbronn M, Roth T. Disturbed sleep in patients complaining of chronic pain. *J Nerv Ment Dis.* 1982;170(7):429-31.
149. Horne JA, Shackell BS. Alpha-like EEG activity in non-REM sleep and the fibromyalgia (fibrositis) syndrome. *Electroencephalogr Clin Neurophysiol.* 1991;79(4):271-6.
150. Branco J, Atalaia A, Paiva T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. *J Rheumatol.* 1994;21(6):1113-7.
151. Drewes AM, Gade K, Nielsen KD, Bjerregard K, Taagholt SJ, Svendsen L. Clustering of sleep electroencephalographic patterns in patients with the fibromyalgia syndrome. *Br J Rheumatol.* 1995;34(12):1151-6.
152. Drewes AM, Nielsen KD, Taagholt SJ, Bjerregard K, Svendsen L, Gade J. Sleep intensity in fibromyalgia: focus on the microstructure of the sleep process. *Br J Rheumatol.* 1995;34(7):629-35.
153. Perlis ML, Giles DE, Bootzin RR, et al. Alpha sleep and information processing, perception of sleep, pain, and arousability in fibromyalgia. *Int J Neurosci.* 1997;89(3-4):265-80.

154. Dauvilliers Y, Touchon J. [Sleep in fibromyalgia: review of clinical and polysomnographic data.] *Neurophysiol Clin.* 2001;31(1):18-33.
155. Tayag-Kier CE, Keenan GF, Scalzi LV, et al. Sleep and periodic limb movement in sleep in juvenile fibromyalgia. *Pediatrics.* 2000;106(5):E70.
156. Schneider-Helmert D, Whitehouse I, Kumar A, Lijzenga C. Insomnia and alpha sleep in chronic non-organic pain as compared to primary insomnia. *Neuropsychobiol.* 2001;43(1):54-8.
157. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. *Harv Rev Psychiatry.* 2000;8(6):298-306.
158. Lentz MJ, Landis CA, Rothermel J, Shaver JL. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. *J Rheumatol.* 1999;26(7):1586-92.
159. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. *Psychosom Med.* 1975;37(4):341-51.
160. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. *Psychosom Med.* 1976;38(1):35-44.
161. Moldofsky H. Fibromyalgia, sleep disorder and chronic fatigue syndrome. *Ciba Found Symp.* 1993;173:262-71.
162. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. *Arthritis Rheum.* 1997;40(11):1928-39.
163. Scharf MB, Hauck M, Stover R, McDannold M, Berkowitz D. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. *J Rheumatol.* 1998;25(10):1986-90.
164. Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. *Arthritis Rheum.* 1995;38(9):1211-7.
165. Johansson G, Risberg J, Rosenhall U, Orndahl G, Svennerholm L, Nystrom S. Cerebral dysfunction in fibromyalgia: evidence from regional cerebral blood flow measurements, otoneurological tests and cerebrospinal fluid analysis. *Acta Psychiatr Scand.* 1995;91(2):86-94.
166. Lekander M, Fredrikson M, Wik G. Neuroimmune relations in patients with fibromyalgia: a positron emission tomography study. *Neurosci Lett.* 2000;282(3):193-6.
167. Alavi A, Hirsch LJ. Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography: evolution over the past 2 decades. *Semin Nucl Med.* 1991;21(1):58-81.
168. Detre JA, Floyd TF. Functional MRI and its applications to the clinical neurosciences. *Neuroscientist.* 2001;7(1):64-79.
169. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. *Cell Mol Neurobiol.* 1999;19(4):467-89.
170. San Pedro EC, Mountz JM, Mountz JD, Liu HG, Katholi CR, Deutsch G. Familial painful restless legs syndrome correlates with pain dependent variation of blood flow to the caudate, thalamus, and anterior cingulate gyrus. *J Rheumatol.* 1998;25(11):2270-5.
171. Hsieh JC, Belfrage M, Stone-Elander S, Hansson P, Ingvar M. Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. *Pain.* 1995;63(2):225-36.
172. Di Piero V, Jones AK, Iannotti F, et al. Chronic pain: a PET study of the central effects of percutaneous high cervical cordotomy. *Pain.* 1991;46(1):9-12.
173. Iadarola MJ, Max MB, Berman KF, et al. Unilateral decrease in thalamic activity observed with positron emission tomography in patients with chronic neuropathic pain. *Pain.* 1995;63(1):55-64.
174. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. *J Psychiatr Res.* 1997;31(4):393-432.
175. Reiman EM. The application of positron emission tomography to the study of normal and pathologic emotions. *J Clin Psychiatry.* 1997;58(Suppl 16):4-12.
176. Gracely RH, Kwilosz DM. The Descriptor Differential Scale: applying psychophysical principles to clinical pain assessment. *Pain.* 1988;35(3):279-88.
177. Arnold LM, Keck PE, Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. *Psychosomatics.* 2000;41(2):104-13.
178. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. *J Gen Intern Med.* 2000;15(9):659-66.
179. Wolfe F. Fibromyalgia. *Rheum Dis Clin North Am.* 1990;16(3):681-698.
180. Burckhardt CS, O'Reilly CA, Wiens AN, Clark SR, Campbell SM, Bennett RM. Assessing depression in fibromyalgia patients. *Arthritis Care Res.* 1994;7(1):35-9.
181. Hamilton M. Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol.* 1967;6(4):278-96.

182. Hamilton M. Rating depressive patients. *J Clin Psychiatry*. 1980;41(12 Pt 2):21-4.
183. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry*. 1979;134:382-9.
184. Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961;4:561-71.
185. Bennett RM. The rational management of fibromyalgia patients. *Rheum Dis Clin North Am*. 2002;28(2):181-199, v.
186. Buskila D. Drug Therapy. *Baillière's Clin Rheumatol*. 1999;13(3):479-85.
187. Bennett RM. Pharmacological treatment of fibromyalgia. *J Functional Syndromes*. 2001;1(1):79-92.
188. Lautenschlager J. Present state of medication therapy in fibromyalgia syndrome. *Scand J Rheumatol Suppl*. 2000;113:32-6.
189. Miller LJ, Kubes KL. Serotonergic agents in the treatment of fibromyalgia syndrome. *Ann Pharmacother*. 2002;36(4):707-12.
190. Barkhuizen A. Pharmacologic treatment of fibromyalgia. *Curr Pain Headache Rep*. 2001;5(4):351-8.
191. Rao SG, Bennett RM. Pharmacological therapies in fibromyalgia. *Best Pract Res Clin Rheumatol*. 2003;17(4):611-27.
192. Arnold LM, Lu Y, Crofford LJ, et al. A Double-Blind, Multicenter Trial Comparing Duloxetine to Placebo in the Treatment of Fibromyalgia With or Without Major Depressive Disorder. Paper presented at: American College of Rheumatology: 67th Annual Meeting; 2003, 2003; Orlando.
193. Rao SG. The neuropharmacology of centrally-acting analgesic medications in fibromyalgia. *Rheum Dis Clin North Am*. 2002;28(2):235-59.
194. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). *Int Clin Psychopharmacol*. 1994;9 Suppl 1:19-26.
195. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. *Eur J Pharmacol*. 1997;340(2-3):249-58.
196. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. *J Pharmacol Exp Ther*. 1997;283(3):1305-22.
197. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. Biochemical profile of mirtazapine (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. *Neuropharmacol*. 1985;24(12):1211-9.
198. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Mirtazapine: a comparative analysis of human monoamine uptake and transporter binding affinity. *Biol Psychiatry*. (In Press) 2004.
199. Rao S. Monoamine reuptake and NMDA antagonist profile of mirtazapine: a comparison to duloxetine. Paper presented at: Society for Neuroscience, 32nd Annual Meeting; 2002, 2002; Orlando, FL.
200. Beique JC, de Montigny C, Blier P, Debonnel G. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. *Br J Pharmacol*. 1998;125(3):526-32.
201. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. *Arch Gen Psychiatry*. 2000;57(5):503-509.
202. Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. *Depress Anxiety*. 2000;12(Suppl 1):20-9.
203. Nemeroff CB, Owens MJ. Neuropharmacology of paroxetine. *Psychopharmacol Bull*. Spring 2003;37 Suppl 1:8-18.
204. Celiker R, Cagavi Z. Comparison of amitriptyline and sertraline in the treatment of fibromyalgia syndrome; 2001.
205. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. *Arthritis & Rheumatism*. 1996;39(11):1852-59.
206. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomäki R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. *Br J Rheumatol*. 1998;37(12):1279-86.
207. Watson CP, Chipman M, Reed K, Evans RJ, Birkett N. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. *Pain*. 1992;48(1):29-36.
208. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med*. 1992;326(19):1250-6.
209. Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. *Anesthesiol*. 1995;83(5):1046-54.
210. Reynolds IJ, Miller RJ. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. *Br J Pharmacol*. 1988;95(1):95-102.

211. McCaslin PP, Yu XZ, Ho IK, Smith TG. Amitriptyline prevents N-methyl-D-aspartate (NMDA)-induced toxicity; does not prevent NMDA-induced elevations of extracellular glutamate, but augments kainate-induced elevations of glutamate. *J Neurochem*. 1992;59(2):401-5.
212. Cai Z, McCaslin PP. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-aspartate-induced intracellular Ca²⁺ levels in neuronal culture. *Eur J Pharmacol*. 1992;219(1):53-7.
213. Watanabe Y, Saito H, Abe K. Tricyclic antidepressants block NMDA receptor-mediated synaptic responses and induction of long-term potentiation in rat hippocampal slices. *Neuropharmacol*. 1993;32(5):479-86.
214. Kuo CC. Imipramine inhibition of transient K⁺ current: an external open channel blocker preventing fast inactivation. *Biophys J*. 1998;75(6):2845-57.
215. Nakazawa K, Inoue K, Ohno Y. Block and unblock by imipramine of cloned and mutated P2X2 receptor/channel expressed in *Xenopus* oocytes. *Neurosci Lett*. 1999;264(1-3):93-6.
216. Park TJ, Shin SY, Suh BC, et al. Differential inhibition of catecholamine secretion by amitriptyline through blockage of nicotinic receptors, sodium channels, and calcium channels in bovine adrenal chromaffin cells. *Synapse*. 1998;29(3):248-56.
217. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. *Lancet*. 2000;355(9207):911-8.
218. Schatzberg AF. Noradrenergic versus serotonergic antidepressants: predictors of treatment response. *J Clin Psychiatry*. 1998;59 Suppl 14:15-8.
219. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE, Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. *Am J Med*. 2002;112(3):191-7.
220. Capaci K, Hepguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. *The Pain Clinic*. 2002;14(3):223-8.
221. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. *Scand J Rheumatol*. 1994;23(5):255-259.
222. Norregaard J, Volkmann H, Danneskiold-Samsøe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. *Pain*. 1995;61(3):445-9.
223. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia—a randomized, double-blind, placebo-controlled study. *Eur J Pain: EJP*. 2000;4(1):27-35.
224. Celiker R, Cagavi Z. Comparison of amitriptyline and sertraline in the treatment of fibromyalgia syndrome. Poster presented at: 20th Annual Scientific Meeting of the American Pain Society; April 20, 2001; Phoenix, AZ.
225. Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. *Arch Intern Med*. 2002;162(1):19-24.
226. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. *Headache*. 1992;32(2):101-4.
227. Saper JR, Silberstein SD, Lake AE, 3rd, Winters ME. Fluoxetine and migraine: comparison of double-blind trials. *Headache*. 1995;35(4):233.
228. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE, Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. *Psychosomatics*. 1998;39(1):14-7.
229. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. *Ann Pharmacother*. 2003;37(11):1561-5.
230. Zijlstra TR, Barendregt PJ, van de Laar MA. Venlafaxine in Fibromyalgia: Results of a Randomized, Placebo-controlled, Double-blind Trial. *Arthritis Rheum*. 2002;46(9 (Supplement)):S105.
231. Ginsberg F, Joos E, Geczy J, Bruhwiler J, Vandekerckhove K, Farnacy JP. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. *J Musculoskeletal Pain*. 1998;6:5-17.
232. Besse D, Lombard MC, Zajac JM, Roques BP, Besson JM. Pre- and post-synaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. *Brain Res*. 1990;521:15-22.
233. Duale C, Raboisson P, Molat JL, Dallel R. Systemic morphine reduces the wind-up of trigeminal nociceptive neurons. *Neuroreport*. 2001;12:2091-6.
234. Gendreau RM, Nemeroff CB, Kranzler JD, Clauw DJ, Rao SG. Cypress Bioscience, Inc.'s Milnacipran Significantly Improves Pain and Fatigue in Fibromyalgia Syndrome Patients. *Cypress Bioscience, Inc.* Available at: <http://www.cypressbio.com/corp/news/press/releases/20021210.pdf>. Accessed 2002.
235. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. *J Rheumatol*. 1991;18(5):728-33.
236. Browne JJ, Chong S. The use of reboxetine in fibromyalgia and neuropathic pain; an open, non-randomised, prospective study. Paper presented at: 10th World Congress of Pain; 2002; San Diego, CA.

237. Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. *Pain*. 1999;83(2):137-45.
238. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. *Pain*. 1999;83(3):389-400.
239. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. *Harv Rev Psychiatry*. 2000;7(5):257-77.
240. Brannon GE, Stone KD. The use of mirtazapine in a patient with chronic pain. *J Pain Symptom Manage*. 1999;18(5):382-5.
241. Hickie IB, Wilson AJ, Wright JM, Bennett BK, Wakefield D, Lloyd AR. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. *J Clin Psychiatry*. 2000;61(9):643-8.
242. Ginsberg F, Joos E, Geczy J, Bruhwyler J, Vandekerckhove K, Famaey JP. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. *J Musculoskeletal Pain*. 1998;6(2):5-17.
243. Davidson J, Krishnan R, France R, Pelton S. Neurovegetative symptoms in chronic pain and depression. *J Affect Disord*. 1985;9(3):213-18.
244. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. *Arthritis Rheum*. 1997;40(9):1560-70.
245. Thomas RJ. Excitatory amino acids in health and disease. *J Am Geriatr Soc*. 1995;43(11):1279-89.
246. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. *Drugs*. 2000;60(5):1029-52.
247. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. *CNS Drugs*. 2001;15(5):339-50.
248. Crofford LJ, Russell IJ, Mease P, et al. Pregabalin improves pain associated with fibromyalgia syndrome in a multicenter, randomized, placebo-controlled monotherapy trial. Paper presented at: American College of Rheumatology, 66th Annual Scientific Meeting; 2002; New Orleans, LA.
249. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K⁺-evoked [³H]-norepinephrine release from rat neocortical slices. *Synapse*. 2002;45(3):171-90.
250. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. *Jama*. 1998;280(21):1837-42.
251. Backonja MM. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. *Epilepsia*. 1999;40(Suppl 6):S57-59; discussion S73-4.
252. McCleane GJ. Lamotrigine in the management of neuropathic pain: a review of the literature. *Clin J Pain*. 2000;16(4):321-6.
253. Martinez-Salio A, Porta-Etessam J, Berbel-Garcia A, Garcia-Morales I, de la Pena-Mayor P, Vicente-Fatela L. [Antiepileptic drugs and neuropathic pain.] *Rev Neurol*. 2001;32(4):345-50.
254. Conner GS. Efficacy of the antiepileptic topiramate in treatment-resistant diabetic or idiopathic neuropathy. Paper presented at: American Pain Society, 2000; Phoenix, AZ.
255. Sawynok J. GABAergic mechanisms of analgesia: an update. *Pharmacol Biochem Behav*. 1987;26:463-74.
256. Caccia MR. Clonazepam in facial neuralgia and cluster headache. Clinical and electrophysiological study. *Eur Neurol*. 1975;13(6):560-563.
257. Smirne S, Scarlato G. Clonazepam in cranial neuralgias. *Med J Aust*. 1977;1(4):93-4.
258. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. *Neurol*. 1988;38(9):1427-32.
259. Russell IJ, Fletcher EM, Michalek JE, McBroome PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. *Arthritis Rheum*. 1991;34(5):552-60.
260. Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J, et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *Pain*. 1996;65(2-3):221-5.
261. Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. *J Rheumatol*. 1996;23(3):529-33.
262. Gronblad M, Nykanen J, Kontinen Y, Jarvinen E, Helve T. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. *Clin Rheumatol*. 1993;12(2):186-91.

263. Drewes AM, Andreassen A, Jennum P, Nielsen KD. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. *Scand J Rheumatol*. 1991;20(4):288-93.
264. Citera G, Arias MA, Maldonado-Cocco JA, et al. The effect of melatonin in patients with fibromyalgia: a pilot study. *Clin Rheumatol*. 2000;19(1):9-13.
265. Wikner J, Hirsch U, Wetterberg L, Rojdmarm S. Fibromyalgia—a syndrome associated with decreased nocturnal melatonin secretion. *Clin Endocrinol (Oxf)*. 1998;49(2):179-83.
266. Webb SM. Fibromyalgia and melatonin: are they related? *Clin Endocrinol (Oxf)*. 1998;49(2):161-2.
267. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men. *J Clin Invest*. 1997;100(3):745-53.
268. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. *J Rheumatol*. 2003;30(5):1070-4.
269. Santandrea S, Montrone F, Sarzi-Puttini P, Boccassini L, Caruso I. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. *J Int Med Res*. 1993;21(2):74-80.
270. Moldofsky H, Cesta A, Reynolds WJ, et al. A Double-Blind, Randomized, Parallel Study of the Safety, Efficacy and Tolerability of Very Low-Dosage Cyclobenzaprine Compared to Placebo in Subjects with Fibromyalgia. *Arthritis and Rheumatism*. 2002;46(9 (Supplement)):S614.
271. Kameyama T, Nabeshima T, Matsuno K, Sugimoto A. Comparison of alpha-adrenoceptor involvement in the antinociceptive action of tizanidine and clonidine in the mouse. *Eur J Pharmacol*. 1986;125(2):257-64.
272. Nabeshima T, Matsuno K, Sugimoto A, Kameyama T. Antinociceptive activity induced by tizanidine and alpha 2-adrenoreceptors. *Neuropharmacol*. 1987;26(10):1453-5.
273. Russell IJ, Michalek JE, Xiao Y, Haynes W, Vertiz R, Lawrence RA. Therapy with a central alpha-2-adrenergic agonist [tizanidine] decreases cerebrospinal fluid substance P, and may reduce serum hyaluronic acid as it improves the clinical symptoms of the fibromyalgia syndrome. *Arthritis Rheum*. 2002;46(9 (Supplement)):S614.
274. Fromm GH. Baclofen as an adjuvant analgesic. *J Pain Symptom Manage*. 1994;9(8):500-9.
275. Steardo L, Leo A, Marano E. Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial. *Eur Neurol*. 1984;23(1):51-5.
276. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. *Ann Neurol*. 1984;15(3):240-4.
277. Panerai AE, Vecchiet J, Panzeri P, et al. Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. *Clin J Pain*. 2002;18(4):270-3.
278. Marbach JJ. Medically unexplained chronic orofacial pain. Temporomandibular pain and dysfunction syndrome, orofacial phantom pain, burning mouth syndrome, and trigeminal neuralgia. *Med Clin North Am*. 1999;83(3):691-710, vi-vii.
279. Deyo RA. Drug therapy for back pain. Which drugs help which patients? *Spine*. 1996;21(24):2840-2849; discussion 2849-50.
280. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. *Scand J Rheumatol*. 1995;24(6):360-5.
281. Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. *Int J Clin Pharmacol Res*. 1998;18(1):13-9.
282. Russell IJ, Kamin M, Bennett R, Schnitzer T, Green J, Katz W. Efficacy of tramadol in treatment of pain in fibromyalgia. *J Clin Rheumatol*. 2000;6:250-7.
283. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. *Am J Med*. 2003;114(7):537-45.
284. Wolf H. Preclinical and clinical pharmacology of the 5-HT₃ receptor antagonists. *Scand J Rheumatol Suppl*. 2000;113:37-45.
285. Hamon M, Gallissot MC, Menard F, Gozlan H, Bourgoin S, Verge D. 5-HT₃ receptor binding sites are on capsaicin-sensitive fibres in the rat spinal cord. *Eur J Pharmacol*. 1989;164(2):315-22.
286. Saria A, Javorsky F, Humpel C, Gamse R. 5-HT₃ receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. *Neuroreport*. 1990;1(2):104-6.
287. Sawynok J, Reid A. Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. *Behav Brain Res*. 1996;73(1-2):63-8.
288. Farber L, St ratz T, Bruckle W, et al. Efficacy and tolerability of tiroprisetrin in primary fibromyalgia—a highly selective and competitive 5-HT₃ receptor antagonist. German Fibromyalgia Study Group. *Scand J Rheumatol Suppl*. 2000;113:49-54.

289. Haus U, Varga B, Stratz T, Spath M, Muller W. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. *Scand J Rheumatol Suppl.* 2000;113:55-8.
290. Hocheil K, Farber L, Ladenburger S, et al. Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia. *Scand J Rheumatol Suppl.* 2000;113:46-8.
291. Muller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. *Scand J Rheumatol Suppl.* 2000;113:59-62.
292. Papadopoulos IA, Georgiou PE, Katsimbri PP, Drosos AA. Treatment of fibromyalgia with tropisetron, a 5HT₃ serotonin antagonist: a pilot study. *Clin Rheumatol.* 2000;19(1):6-8.
293. Samborski W, Stratz T, Lacki JK, Klama K, Mennet P, Muller W. The 5-HT₃ blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose. *Mater Med Pol.* 1996;28(1):17-9.
294. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. *Pain.* 2000;85(3):483-91.
295. Clark SR, Bennett RM. Supplemental dextromethorphan in the treatment of fibromyalgia: a double-blind, placebo-controlled study of efficacy and side-effects. *Arth Rheum.* 2000;43:S333.
296. Littman BH, Newton FA, Russell IJ. Substance P antagonism in fibromyalgia: a trial with CJ-11974. Paper presented at: 9th World Conference on Pain, 1999; Seattle, WA.
297. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. *Am J Med.* 1998;104(3):227-31.
298. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. *J Appl Physiol.* 1991;70(2):688-94.
299. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. *J Appl Physiol.* 1991;70(2):695-700.
300. Almqvist O, Thoren M, Saaf M, Eriksson O. Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study. *Psychoneuroendocrinol.* 1986;11(3):347-52.
301. McGauley GA, Cuneo RC, Salomon F, Sonksen PH. Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. *Horm Res.* 1990;33(Suppl 4):52-4.
302. Mannerkorpi K, Iversen MD. Physical exercise in fibromyalgia and related syndromes. *Best Pract Res Clin Rheumatol.* 2003;17(4):629-47.
303. Cypress bioscience, inc. Announces milnacipran clinical study. Results demonstrating that effective treatment of fibromyalgia-related. Pain is distinct from the treatment of mood. [Press Release.] Available at: <http://www.cypressbio.com/corp/news/press/releases/20031211.pdf>. Accessed 2003.